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Children talk about living with 
problem drug and alcohol use
‘She knew not to go near me in the morning ’til I had my foil, then ‘mummy would play’. In 
the mornings the sickness was the worst… I’d just be telling her to get away. Once I had the 
gear [drugs] into me I’d be the best mother on the earth.’ 
These words were spoken by a mother of a four-year-old girl interviewed as part of a research 
study in Ireland published last year. It is quoted in a new EMCDDA thematic paper on 
European children’s experiences and perceptions of drug and alcohol issues, published to mark 
International Children’s Day on 1 June.1 
Drugs come under 
new department 
Following the reorganisation of government departments 
announced on 23 March 2010, the Office of the Minister 
for Drugs (OMD) is now located in the new Department 
of Community, Equality and Gaeltacht Affairs (DCEGA). 
Chief Whip Pat Carey TD, who was Minister of State 
with responsibility for drugs strategy and community 
affairs for 11 months between June 2007 and May 2008, 
was appointed Minister for Community, Equality and 
Gaeltacht Affairs, including responsibility for the National 
Drugs Strategy and the OMD. 
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Drugs come under new department (continued)
Explaining the reconfiguration of the DCEGA, the Taoiseach said:1
It is important, while addressing the priority issues in responding to 
unemployment and driving economic recovery, that we do not lose 
sight of the importance of social development, the targeting of the 
most vulnerable and support for those working to make a difference 
right across our communities. I have therefore decided that the 
Department of Community, Rural and Gaeltacht Affairs will become 
the Department of Community, Equality and Gaeltacht Affairs and will 
incorporate responsibility for social inclusion policy and family policy 
from the Department of Social and Family Affairs and for equality, 
disability, integration and human rights from the Department of Justice, 
Equality and Law Reform.
In the reorganisation, former Minister for Community, Rural and Gaeltacht Affairs, Eamon Ó Cuív TD, 
went as minister to the new Department of Social Protection, and the former minister of state with 
responsibility for drugs strategy and community affairs, John Curran TD, was appointed Government 
Chief Whip.
Mary White TD was appointed Minister of State at the 
departments of Justice and Law Reform, Community, 
Equality and Gaeltacht Affairs, and Education and Skills, 
with special responsibility for equality and human 
rights, and integration. It may be expected that the 
issue of drugs will come within her purview as well. In 
recent years, explicit policy commitments to recognise 
and address the human rights issues involved in drug 
control have been made at both UN and EU levels.2 
With regard to equality, Drugnet Ireland regularly reports 
on research highlighting how the drugs issue impacts 
on members of groups vulnerable to discrimination 
and provided for under Ireland’s equality legislation, 
including young people, women, and members of the 
LGBT community, of new Irish communities and of the 
Traveller community.3 
(Brigid Pike)
Cowen B (2010, 23 March) 1. Parliamentary Debates Dáil Éireann (Official report: unrevised): 
Nomination of members of government: motion. Vol. 705, No. 1, p. 9.  
Available at http://debates.oireachtas.ie/Xml/30/DAL20100323.PDF
See Pike B (2009) 2. Development of Ireland’s drug strategy 2000–2007. Overview Series 8. Dublin: 
Health Research Board. pp. 99–101. 
Under the Equal Status Acts 2000–2004, discrimination is prohibited on nine grounds, including 3. 
gender, marital status, family status, sexual orientation, religion, age, disability, race, and 
membership of the Traveller community.
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3The purpose of the paper is to enhance drug policies and 
interventions for children and young people by highlighting 
children’s and young people’s perspectives and their needs. 
Comprising quotations selected from research studies and 
governmental and non-governmental reports in 14 EU 
countries, including Ireland, the thematic paper gives voice 
to four main issues:
living with harmful parental drinking or drug taking  ■
(neglect, violence, abuse, stigma or shame),
being separated from parents and looked after by  ■
relatives, foster carers or institutions,
experiences and perceptions of alcohol and drug  ■
consumption, and
experiences and perceptions of interventions to address  ■
alcohol and drug consumption. 
The authors consulted three Irish sources2 and used quotations 
from them to highlight issues associated with living with 
parents engaging in harmful substance use, and children’s 
and young people’s own experience of substance use. For 
example, an Irish child care worker is quoted on the effect of 
living with a parent engaging in harmful substance use:
‘They become adults very young; they’re like the carer 
to their parent. They actually know, you can see it in 
them, that they know when their parent isn’t well… it 
seems to be a constant worry.’ 
Looking back, a young Irish woman who had been abused 
by a member of her extended family during her childhood 
recalled her teenage years: 
‘I turned 15 that January, I just went wild then you 
know after that like. I did have problems at home … 
Like when I was growing up, that would have been the 
start of it, but then I just used to go wild you know with 
the problems and the issues that I did have, I’d end up 
going drinking and taking drugs, you know, and not 
having any, no self-respect or anything for myself.’
In concluding the report, the authors make several 
observations:
given the complexity and diversity of children’s  ■
experiences, correspondingly flexible and holistic 
interventions need to be developed; 
more qualitative drug and alcohol research is needed if  ■
Europe is to understand the real needs of children and 
young people and to implement fully the United Nations 
Convention on the Rights of the Child (UNCRC); 
large numbers of parents with alcohol problems may  ■
generate more problems overall for children in the EU 
than the smaller number of children affected by parents 
with illicit drug problems;
the quotations highlight children’s extreme vulnerability,  ■
and yet also their desire and capacity to ‘cope’ with 
difficulties and to make rational judgements about 
their own situation based on objective information and 
personal experience; 
while quality care and other drug and alcohol  ■
interventions are needed to grant children in the EU their 
right to ‘harmonious development and protection from 
harmful influences’, abuse, neglect and exploitation, 
the root cause for many children facing both drug and 
alcohol problems are poverty and social exclusion.
(Brigid Pike)
Olszewski D, Burkhart G and Bo A (2010) 1. Children’s 
voices: experiences and perceptions of European children on 
drug and alcohol issues. Thematic paper. Luxembourg: 
The Publications Office of the European Union. Available 
at www.emcdda.europa.eu 
The three Irish research studies used in the EMCDDA 2. 
thematic paper were Bates T, Illback RJ, Scanlan F and 
Carroll L (2009) Somewhere to turn to, someone to talk 
to. Dublin: Headstrong – The National Centre for Youth 
Mental Health; Mayock P (2000) Choosers or losers: 
influences on young people’s choices about drugs in inner-
city Dublin. Dublin: Children’s Research Centre, TCD; 
Mayock P and Carr N (2008) Not just homelessness …  
A study of ‘out of home’ young people in Cork city. Dublin: 
Children’s Research Centre, TCD. These three research 
reports are available at www.drugsandalcohol.ie
Children talk about living with problem drug and alcohol use (continued)
Cuan Mhuire, which has provided detoxification and 
residential rehabilitation services in Ireland since 1966, has 
won the prestigious CHKS Quality Improvement Award 
2010. This international award recognises significant 
improvements in patient care and patient experience, as well 
as in staff welfare, safety and morale. Candidate institutions 
are evaluated by experts representing medical and nursing 
colleges, healthcare associations and national quality 
institutes. It is the first time that this award has been give 
to a rehabilitation service. Speaking at the award ceremony 
in London in May, Cuan Mhuire founder Sister Consilio 
Fitzgerald said: ‘This Award shows how vocationally driven 
organisations such as Cuan Mhuire can deliver cost-effective 
services with the highest possible standards of care. The 
intrinsic value of each human being before God demands 
no less than our committed love.’ Cuan Mhuire provides a 
range of services in its communities in Dublin, Kildare, Cork, 
Limerick, Tipperary, Galway, Monaghan and Newry. Between 
them the services had over 3,000 users in 2009. Cuan 
Mhuire is a voluntary body and a charitable trust.
Cuan Mhuire wins international quality 
improvement award
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4Poisoning deaths
The annual number of deaths by poisoning increased from 
178 in 1998 to 274 in 2007 (Table 1). The majority of cases 
in the 10-year period were aged between 20 and 40 years; 
the median age was 34 years. Males accounted for 68% of 
deaths in the 10 years.
Just over half of all deaths by poisoning involved more than 
one substance (polysubstance cases). Heroin and other 
opiates, including methadone, were implicated in over half 
(55.3%, 1,172) of all cases. Cocaine was implicated in 10% 
of all cases in the 10-year period, with the annual number 
rising from five in 1998 to 63 in 2007. Prescription and over-
the-counter medication was implicated in many of the 
deaths by poisoning. Benzodiazepines continued to play a 
major role in polysubstance poisonings.
Since 2003, more deaths by poisoning occurred outside 
Dublin than inside Dublin (city and county). The number 
of poisoning deaths increased in all but two of the regional 
drugs task force (RDTF) areas between 1998 and 2007. The 
South Western RDTF area recorded the highest number of 
deaths (n=478) for the 10-year period. 
Non-poisoning deaths 
A total of 1,345 non-poisoning deaths among drug users was 
recorded between 1998 and 2007. Of the 1,183 cases with a 
known cause of death, 60.3% (714) were due to trauma and 
40% (469) were due to medical causes (Figure 1).
Update on drug-related deaths
Table 1 Drug-related deaths, by year of death, NDRDI 1998 to 2007 (N=3,465)
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
All deaths 242 271 261 277 338 297 365 447 491 476
Poisoning ( n=2120) 178 187 182 178 211 185 207 248 270 274
Non-poisoning (n=1345) 64 84 79 99 127 112 158 199 221 202
National Drug-Related Deaths Index (NDRDI) figures on 
drug-related deaths and deaths among drug users in 2006 
and 2007 are now available on the web.1 Previously reported 
figures for the years 1998–2005 have been updated to 
include data from the Coroner Service on late inquests. 
Similarly, figures for the years 2006 and 2007 will be revised 
when data relating to late inquests becomes available. 
Between 1998 and 2007 a total of 3,465 drug-related deaths 
and deaths among drug users met the criteria for inclusion 
in the NDRDI database. Of these deaths, 2,120 were due 
to poisoning and 1,345 were due to traumatic or medical 
causes (non-poisoning) (Table 1). The annual number of 
deaths more than doubled in nine years, rising from 242 in 
1998 to 491 in 2006. The number fell to 476 in 2007, but 
this figure may be revised upwards when data relating to late 
inquests becomes available. In 1998, almost three-quarters 
(73.6%) of drug-related deaths recorded in the NDRDI were 
poisonings. The percentage of such deaths decreased over 
the 10-year reporting period, with 57% of deaths in 2007 
due to poisoning and 42% to other causes (non-poisoning).
Figure 1 Non-poisoning deaths among drug users, NDRDI 1998 to 2007 (N=1,183)
Deaths due to trauma
The annual number of deaths due to trauma increased from 39 
in 1998 to 116 in 2006, but decreased to 87 in 2007 (Figure 
1). These figures may be revised when data relating to late 
inquests becomes available. Half (50.4%, 360) of those who 
died from traumatic causes were aged between 20 and 29 
years. The median age was 27 years. Almost all (90.1%, 643) 
of those who died were male. The most common causes of 
death due to trauma were hanging and road traffic collisions.
Deaths due to medical causes
The annual number of deaths due to medical causes rose 
fairly steadily over the reporting period, increasing from 11 in 
1998 to 98 in 2007, when it exceeded the number of deaths 
due to trauma (Figure 1). The majority of those who died 
from medical causes were aged between 30 and 44 years. 
The median age was 39 years. Three-quarters (75.0%, 352) 
of those who died were male. The most common medical 
causes of death were cardiac events (25.2%, 118), respiratory 
infections (17.7%, 83) and liver disease (10.2%, 48).
(Suzi Lyons and Simone Walsh)
Health Research Board (2010). 1. Drug-related deaths and 
deaths among drug users in Ireland, 1998 to 2007. Data 
from the National Drug-Related Deaths Index. Available at 
www.drugsandalcohol.ie/13205 
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5Non-fatal overdoses and drug- 
related emergencies
Data extracted from the Hospital In-Patient Enquiry (HIPE) 
scheme were analysed to determine trends in non-fatal 
overdoses discharged from Irish hospitals in 2008. There 
were 4,815 overdose cases in that year, of which 43 died 
in hospital. The 4,772 discharged cases are included in this 
analysis. The number of overdose cases decreased by 2.9% 
between 2007 and 2008 (Figure 1).
Characteristics of cases
Gender
In the years 2005–2008 there were more overdose cases 
among females than among males (Figure 2), with females 
accounting for 55% of all overdose cases in 2008.
Age group
In the four-year period, one quarter of overdoses occurred 
in those aged 15–24 years, with the incidence of overdose 
decreasing with age (Figure 3). This pattern was similar for 
each of the years reported.
Area of residence
In 2008, 26 overdose cases were resident outside of Ireland 
and 10 cases were recorded as having no fixed abode; these 
36 cases were excluded from this analysis. Figure 4 shows the 
area of residence of cases with an Irish address for the years 
2005–2008. One fifth of cases in 2008 were resident in Dublin.
Drugs involved
Table 1 presents the positive findings per category of drugs 
and other substances involved in all cases of overdose in 
2008. Non-opioid analgesics were present in 34.8% (1,660) 
of cases. Paracetamol is included in this drug category and 
was present in 25% (1,198) of cases. Psychotropic agents 
were taken in 21.5% (1,025) and benzodiazepines in 20.8% 
(993) of cases. There was evidence of alcohol consumption 
in 14.0% (669) of cases. Cases involving alcohol are 
included in this analysis only when the alcohol was used in 
conjunction with another substance.
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Figure 1 Overdose cases by year, 2005–2008  
(N=19,542)
 Source: Unpublished HIPE data
Figure 3 Overdose cases by age group, 2005–2008 
(N=19,542) 
Source: Unpublished HIPE data
Figure 2  Overdose cases by gender, 2005–2008 
(N=19,542) 
Source: Unpublished HIPE data
Figure 4  Overdose cases by area of residence,  
2005–2008 (N=18,510) 
Source: Unpublished HIPE data
6Table 1 Category of drugs involved in overdose cases,  
2008 (N=4,772)
Drug category Positive 
findings per 
drug category*
n %
Non-opioid analgesics 1660 34.8
Psychotropic agents 1025 21.5
Benzodiazepines 993 20.8
Alcohol 669 14.0
Narcotics and hallucinogens 599 12.6
Anti-epileptic / Sedative / Anti-
Parkinson agents
569 11.9
Other chemicals and noxious 
substances
316 6.6
Systemic and haematological agents 169 3.5
Autonomic nervous system agents 117 2.5
Cardiovascular agents 110 2.3
Hormones 109 2.3
Systemic antibiotics 92 1.9
Anaesthetics 90 1.9
Gastrointestinal agents 65 1.4
Other gases and vapours 52 1.1
Muscle and respiratory agents 52 1.1
Anti-infectives / Anti-parasitics 40 0.8
Diuretics 38 0.8
Topical agents 24 0.5
Other and unspecified drugs 969 20.3
*The sum of positive findings is greater than the total 
number of cases because some cases involved more than 
one drug or substance.  
Source: Unpublished data from HIPE
Overdoses involving narcotics or hallucinogens
Narcotic or hallucinogenic drugs were involved in 12.6% 
(599) of overdose cases in 2008. Figure 5 shows the number 
of positive findings of drugs in this category among the 599 
cases. The sum of positive findings is greater than the total 
number of cases because some cases involved more than 
one drug from this category. Opiates were used in half of 
the cases, cocaine in one fifth and cannabis in 7%.
Figure 5  Narcotics and hallucinogens involved in 
overdose cases, 2008 (N=599) 
Source: Unpublished data from HIPE
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Overdoses classified by intent
In two-thirds (65.5%) of cases the overdose was classified as 
intentional (Figure 6).
Figure 6  Overdose cases by classification, 2008 
(N=4,772) 
Source: Unpublished data from HIPE
 
Table 2 presents the positive findings per category of drugs 
and other substances involved in cases of intentional 
overdose in 2008. Non-opioid analgesics were involved in 
43% (1,346) of cases, psychotropic agents in 26% (806) and 
benzodiazepines in 25% (772).
Table 2 Category of drugs involved in intentional 
overdose cases, 2008 (N=3,126)
Drug category Positive 
findings per 
drug category*
n %
Non-opioid analgesics 1346 43.1
Psychotropic agents 806 25.8
Benzodiazepines 772 24.7
Alcohol 476 15.2
Anti-epileptic / Sedative / Anti-
Parkinson agents
461 14.7
Narcotics and hallucinogens 304 9.7
Systemic and haematological agents 96 3.1
Other chemicals and noxious 
substances
84 2.7
Autonomic nervous system agents 77 2.5
Cardiovascular agents 75 2.4
Hormones 70 2.2
Systemic antibiotics 69 2.2
Gastrointestinal agents 50 1.6
Anaesthetics 44 1.4
Muscle and respiratory agents 29 0.9
Anti-infectives / Anti-parasitics 28 0.9
Diuretics 22 0.7
Other gases and vapours 16 0.5
Topical agents 9 0.3
Other and unspecified drugs 576 18.4
*The sum of positive findings is greater than the total 
number of cases because some cases involved more than 
one drug or substance.  
Source: Unpublished data from HIPE
(Mairea Nelson and Deirdre Mongan)
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Non-fatal overdoses and drug related emergencies (continued)
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7Guide to substance 
misuse for health 
professionals 
Sinead O’Mahony 
Carey, drug education 
officer with HSE South, 
compiled a pocket-sized 
reference manual, A guide 
to substance misuse for 
medical professionals.1 
The first section of the 
guide presents drugs with 
potential for misuse by 
category and by type. 
The major categories of 
drugs covered include 
hallucinogens, opiates, 
stimulants and volatile 
inhalants. Details of individual drugs are presented under 
each category, described by street name(s), expected effects, 
negative or side effects, appearance, method(s) of use, 
dependency potential, withdrawal symptoms, overdose risk 
and effects of long-term use. The second section contains 
information on the signs of drug use. The third section 
presents an overview of the reasons people use drugs, while 
section four presents the dangers of drug use. The fifth section 
presents a summary of Irish law and drug use, and the final 
section covers the jargon related to drug use. This book is a 
useful guide for health professionals, counsellors, key workers 
and social workers who work with drug users. 
White Paper on crime – discussion document 
The Department of Justice and Law Reform has launched 
the second discussion document as part of the consultation 
process to develop a White Paper on crime. The White Paper, 
due to be completed in 2011, provides a high-level statement 
of government policy, its rationale and the strategies to give 
effect to that policy. The process of consultation involves 
the publication of thematic discussion documents. The first 
discussion document, published in July 2009, was entitled 
Crime prevention and community safety and invited submissions 
on a range of subjects such as: reducing opportunities for 
crime; developing locally based partnerships; preventing 
first-time criminality among those most at risk, and reducing 
re-offending. The process of consultation also involves regional 
seminars and meetings with key stakeholders. The second 
discussion document, Criminal sanctions, considers the purpose 
of sanctions, non-custodial sanctions, imprisonment, and 
sentencing policy and practice, and was published in February 
2010. Written submissions are requested before the end of May 
2010. www.justice.ie/en/JELR/Pages/White_Paper_on_Crime 
First national report from sexual assault treatment units
There are currently six sexual assault treatment units (SATUs) 
in Ireland, located at the Rotunda Hospital (Dublin), South 
Infirmary Victoria University Hospital (Cork), Waterford 
Regional Hospital, Midlands Hospital (Mullingar), Letterkenny 
General Hospital and Galway (Ballybrit). Clinical reports from 
each of these units are combined in the first annual SATU 
report, for 2009.2 
There were 529 attendances at the six units in 2009; 95% 
were female and the mean age was 24 years. Half (51%) of 
all patients who attended had consumed at least four units 
of alcohol in the 12 hours prior to the incident reported, 
8% disclosed that they had taken illegal drugs and 3% were 
concerned that drugs had been used to facilitate sexual 
assault. Irish research has shown that alcohol consumption, 
especially drinking to intoxication, is a feature in a high 
proportion of rape and sexual abuse cases in Ireland,3,4 and 
this report further corroborates those findings.
Prison-based needle exchange
A report assessing the need for prison-based needle exchange 
in Ireland5 details the evolution of drug use, particularly 
injecting drug use, in Irish prisons in the years prior to 2001. It 
describes the association between injecting drug use and the 
spread of blood-borne viral infections among Irish prisoners, 
based on studies in 1999 and 2000. The authors acknowledge 
the development of harm reduction and drug treatment 
services in Irish prisons since 2001. However, they note that 
there are no recent Irish data on the prevalence of blood-
borne viral infections and drug use among prisoners. 
The authors describe the experience of prison needle exchange 
in six countries, where findings indicate that such programmes:
reduced risk behaviours (such as sharing needles and  ■
syringes) and transmission of infection (such as hepatitis 
C and HIV);
did not increase drug consumption or injecting drug use; ■
did not endanger staff or compromise prison safety, and  ■
did, in fact, make prisons a safer place to live and work; 
had other positive outcomes for the prisoners’ health; ■
operated as part of a comprehensive harm   ■
reduction programme. 
The authors note that the introduction of needle exchange 
would not present any ethical, legal or clinical issues which 
could not be addressed by the prison service. 
In summary, prison needle exchange does work in other 
jurisdictions, but the need for this intervention requires 
up-to-date evidence. The NACD and the Irish Prison Service 
will commission a study to examine the prevalence of drug 
use, injecting drug use and drug-related blood-borne viral 
infections among prisoners in Ireland. 
(Contributors: Jean Long, Deirdre Mongan and Johnny Connolly)
Sinead O’Mahony Carey (2008) 1. A guide to substance 
misuse for medical professionals. Kilkenny: HSE South. 
Available at www.drugsandalcohol.ie/12899
Eogan M (2010) 2. First national sexual assault treatment  
unit (SATU) annual clinical report. Dublin: Health  
Service Executive.
Hanly C, Healy D and Scriver S (2009) 3. Rape and justice in 
Ireland: a national study of survivor, prosecutor and court 
responses to rape. Dublin: The Liffey Press.
McGee H, Garavan R, de Barra M, Byrne J and Conroy R 4. 
(2002) The SAVI report: sexual abuse and violence in Ireland. 
Dublin: The Liffey Press.
Forde C, Long J and Davey A (2009) An assessment of 5. 
prison needle-exchange for Ireland. Unpublished report 
submitted to the Oversight Forum on Drugs. 
Drugnet digest
This new feature of the newsletter will contain short summaries of recent research 
reports and other developments of interest. 
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8Key result area Outputs 2009 Deliverables 2010 Due
Implementation of the 
National Drugs Strategy 
(NDS) 2009–2013
Input into preparation of NDS 
completed and strategy launched
National rehabilitation framework in place Q2
Planning undertaken for 
implementation of HSE components
National liaison pharmacist appointed Q1
Rehabilitation Co-ordinator appointed Harm reduction and treatment services further 
developed, including needle-exchange and 
methadone services
Q1
National Drug Rehabilitation 
Implementation Committee established
Recruitment of national liaison 
pharmacist under way
National Addiction Training 
Programme (NATP) developed from 
pilot stage
Development of 
National Substance 
Misuse Strategy 
Input into development of National Substance 
Misuse Strategy completed (co-led by 
Department of Health and Children)
Q4
Source: NSP (2010: 43–44) 
HSE aims to strengthen drug  
services delivery
The Health Service Executive (HSE) National Service Plan 
2010 sets out the agency’s plans in the drugs and alcohol 
area for 2010.1 HSE Drug and Alcohol Services are delivered 
as part of HSE Social Inclusion Services, which also include 
homeless services, services for minority ethnic communities, 
Traveller health services, community development, HSE 
RAPID and CLAR programmes, HIV/STI services, services for 
LGBT communities, and community welfare services.
Social Inclusion Services was part of the Primary, Community 
and Continuing Care (PCCC) directorate. However, in late 
2009, as part of its Transformation Programme, the HSE 
merged the PCCC directorate and the National Directorate 
for Hospitals into a national Integrated Services Directorate 
(ISD). This directorate has responsibility for the delivery, 
reconfiguration, performance and financial management of 
all health and personal social services, including drug and 
alcohol services. A Quality and Clinical Care Directorate 
has also been established. This directorate is intended 
to strengthen clinical leadership and improve clinical 
performance, as well as support the working relationship 
between clinicians and managers across the organisation; 
the participation of clinicians in the management process is 
regarded as a key driver of service development at national, 
regional and local levels. Responsibility for implementation of 
this process lies with the ISD. 
On foot of this realignment, a key focus for the HSE in 2010 
is to integrate the recommendations in the national drugs 
and homeless strategies into the provision of mainstream 
health services, and to put in place a national framework for 
rehabilitation in addiction services. The key result areas and 
deliverables in relation to illicit drugs planned for 2010 are 
set out in the following table.
Regarding drug treatment, in 2010 the HSE plans to increase 
its level of activity and performance as follows:
Average number of clients in methadone treatment per  ■
month per area – in 2009 the HSE exceeded by 136 
its target of having an average of 7,636 clients in 
methadone treatment per month per area; it plans to 
maintain this increased level of throughput in 2010, i.e. 
7,762 clients in methadone treatment per month per 
area. In prisons, the HSE set a target of an average of 
612 clients in methadone treatment per month in 2009; 
however, the projected outturn came in 115 below this 
target and the HSE has adopted this lower figure of 497 
as the target for 2010.
Number of substance misusers under 18 years of age for  ■
whom treatment, as deemed appropriate, commenced 
within one calendar month – in 2009 the percentage 
of substance misusers under 18 years of age for whom 
appropriate treatment was commenced within one 
calendar month exceeded the target of 88%, reaching 
97%. For 2010 the HSE has sets its sights even higher, 
aiming to commence appropriate treatment within one 
calendar month for 100% of drug treatment clients aged 
under 18 years.
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9The Homeless Agency has published a case management 
guidebook for those working in the area of homelessness 
and drugs.1 The guide is intended as a companion to the 
Holistic Needs Assessment and Care Plan, the assessment 
tool developed by the Homeless Agency. The guide and its 
accompanying protocols were piloted among those working 
with the homeless, and their feedback was incorporated into 
the final document. The online version of the guide will be 
updated as necessary.
There are three sections in the guidebook: key support 
interventions, interagency protocols and a listing of services. 
Among the 12 key support areas covered in separate 
chapters are mental health, alcohol use and drug use. These 
three chapters are summarised in this article.
Mental health
Chapter 9 covers how to access mental health services, with 
a section on dual diagnosis (of both addiction and mental 
health problems). The role of the service provider outlined in 
the document is to make appropriate referrals, either to a GP 
or to the psychiatric services (within the addiction services). 
Other areas covered include how to make an application for 
involuntary admission to psychiatric care of a person deemed 
to be a risk to themselves or others, dealing with exclusion 
from the drug services because of mental health issues, and 
non-compliance with medication.
The second part of the mental health chapter deals with 
suicide and deliberate self harm, and how the service 
provider should handle such issues. The association between 
mental health problems and suicide is well known, and 
although self harm is not necessarily associated with suicide, 
it is an indicator of mental health issues.
Alcohol use
Chapter 10 cites evidence that alcohol, frequently combined 
with drugs, may be the most widely misused substance 
among homeless people. The key interventions identified 
are access to detoxification and access to rehabilitation 
and supports. This chapter also deals with the issue of a 
service user who is misusing alcohol while on prescribed 
methadone. The guide advises that in cases of polysubstance 
use an alcohol detoxification should be carried out before 
an opiate detoxification, but that problem use of cocaine 
or amphetamines may have to be addressed before that of 
either alcohol or opiates. Any interventions should be made 
with the support of the prescribing doctor, with aftercare in 
place, along with a relapse prevention plan, including social 
support from family and friends.
Drug use
Chapter 11 outlines key interventions in drug treatment 
services, stressing that they should be seen as a continuum 
of care across services (Figure 1). The interventions are: 
harm reduction services, methadone treatment, stabilisation 
services, detoxification, rehabilitation (day and residential), 
aftercare and support services. Some of these interventions 
are summarised below.
Harm reduction
The guide states that, as many problem drug users start 
injecting before accessing formal drug treatment, it is 
important that the service provider ensures that clients have 
access to harm reduction information and services in order to 
reduce drug-related harm. Such resources may be accessed 
through a client’s own service or by referral to another 
appropriate service. This section summarises the types of 
intervention typically provided by harm reduction services. 
Guidebook on case management in 
homeless and drug services
Number and percentage of substance misusers for whom  ■
treatment, as deemed appropriate, commenced within one 
calendar month – in 2009, 81% (1,365) of substance 
misusers aged 18 years and over entered appropriate 
treatment within one month, which was 3% below 
the target of 1,406 set for the year. In 2010 the HSE 
anticipates that 1,380 substance misusers will seek 
treatment for drug misuse and it is aiming to ensure that 
100% of these clients commence appropriate treatment 
within one calendar month. The graph opposite shows 
how the HSE intends to work towards this target over the 
course of 2010.
(Brigid Pike)
1. Health Service Executive (2010) National Service Plan 2010. 
 Dublin: HSE. Available at www.hse.ie
Source: HSE (2010: 45)
HSE aims to strengthen drug services delivery (continued)
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Methadone treatment
This section gives the service provider an overview of the 
issues around methadone treatment, including assessment, 
changing a prescription, take-aways and polydrug use. It 
includes practical advice, for example what documentation 
the client needs when attending an assessment of suitability 
for treatment. 
Stabilisation services
Stabilisation in this context is taken to mean compliance with 
a methadone treatment programme. This process requires 
input from different services, such as counselling, relapse 
prevention or day programmes to assist and support the 
client. This section outlines some of the different options and 
how to access them.
Detoxification
In general, a person must have be on a reduced daily dose 
of to between 40mg and 60mg of methadone in order to 
qualify for residential detoxification, according to this guide. 
The criteria for other facilities vary, for example some require 
the person to be alcohol free or benzodiazepine free before 
entry. Inpatient facilities give priority to medical emergency 
cases (the type nature of the emergency is not specified), 
and to people who are pregnant, or are under the age of 
18. While benzodiazepine detoxification can be carried 
out by a GP or by the doctor prescribing methadone, the 
guidebook notes that doctors are not obliged to carry out 
such detoxification in the community.
Interagency protocols and listings
The protocols presented in this section were developed 
to help multiple agencies work together and ensure that 
individuals did not fall through the gaps in service provision 
and also to improve the outcomes for those accessing the 
homeless services. The listings section provides information 
and contact details for all relevant services currently available.
(Suzi Lyons)
Homeless Agency Partnership and Progression Routes 1. 
Initiative (2010) Case management guidebook. Dublin: 
Homeless Agency Partnership.
Figure 1 Example of the continuum of care within drug services  
Source: Homeless Agency Partnership (2010: 82)
Guidebook on case management in homeless and drug services (continued)
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Case managers support the individual to access services through interagency negotiation. Some service users will aim to move through
the continuum of care, others may wish to remain at a particular stage for some time.
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Drop-in/outreach
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Treatment clinics, moving onto:
Prescribing GPs
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Evidence-based, or more accurately, evidence-informed, 
policy is now an accepted norm, even if there is debate 
about how the evidence translates into policy. Equally 
important but not so widely debated are the questions (1) 
What is the evidence? and (2) How do policy makers know 
they are using the best evidence available?
For five years between 2004 and 2009, a group of 12 
addiction scientists from different disciplines and with 
affiliations to academic institutions in Australia, Canada, 
Nigeria, Norway, Qatar, Sweden, the UK and the USA, 
collaborated to answer these two questions. The result is a 
300-plus-page book Drug policy and the public good.1
To answer the second question first, what constitutes the 
‘best’ evidence is determined by the purpose of the policy 
– ‘policy for whom and for what?’ – and the nature of the 
‘drug problem’. The authors regard securing the ‘public 
good’ as the purpose of drug policy. They suggest that the 
concept of the public good includes public health aspirations 
but is not restricted to them. Public health is defined as ‘the 
management and prevention of adverse health conditions 
in groups of people, formally termed “populations”.’ It 
can benefit large numbers of people at the level of the 
community or country. The authors regard a public health 
approach as useful in managing the consequences of the use 
of psychoactive substances in a population as it emphasises 
the need to change both the environment and the behavior 
of the individual. However, the authors argue that this 
approach on its own is not enough: it focuses on health 
indicators to the exclusion of broader social indicators such 
as loss of self-esteem or increased anxiety or isolation caused 
by exposure to drug-related problems. 
The purpose of drug policy therefore is seen by the authors 
as heavily influenced by public health concerns but not 
limited to them: ‘… concerns about justice, freedom, 
morality and other issues beyond the health domain have an 
important place in drug policy formation and should not be 
ignored by public health experts.’
The ‘best’ evidence is also determined by the nature of the 
drug problem, which is determined by the manner of use of 
the different substances and the various problems associated 
with their use. In Figure 1 below, the authors summarise 
how the three mechanisms by which harm may be inflicted 
– toxic effects, intoxication and dependence – are related to 
drug dose, use patterns and mode of drug administration, 
and how they mediate the consequences of drug use for the 
individual drug users. The impact of the harm mechanisms 
may also be affected by contextual factors such as the setting 
in which the drug is used and the user’s expectations. 
Using scientific knowledge to inform 
drug policy
Figure 1 How toxic effects, intoxication, and dependence are related to drug dose, use patterns, and mode of 
drug administration, and in turn mediate the consequences of drug use for the individual drug user. 
Source: Babor et al. (2010: 19) 
drugnet 
Ireland
Psychoactive
Dose
Pattern/volume
of psychoactive
dose
Mode of
administration
Context
of use Toxic effects Intoxication Dependence
Effects 
on fetus Overdose
Injury Infectious
disease
Chronic
illness
Role
failures
Social
reaction
to use
Criminal
punishment
stigma
12
While evaluation is an accepted stage in the implementation 
of drug-related programmes and services, there has been 
slower progress in making it a routine part of the national 
policy or strategy cycle. In this regard, the EU Drugs Action 
Plan 2009–2012 includes two actions: 
68: to develop analytical instruments to better assess 
the effectiveness and impact of drug policy (e.g. model 
evaluation tools, policy effectiveness indices, public 
expenditure analysis, etc.), and
70: member states to evaluate and fine-tune national drug 
policies on a regular or ongoing basis. 
In its work programme for 2010, the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) includes 
four activities ‘to support Member States in evaluating their 
national strategies and action plans’:
develop European guidelines for the evaluation of  ■
national drug strategies,
hold Reitox Academy ■ 1 on the evaluation of national  
drug strategies,
launch series of national policy case studies (Portugal to  ■
be first), and
provide tailored support to member states if requested. ■
To date, Ireland’s national drugs strategy has only ever been 
subjected to ‘review’, as distinct from evaluation. While 
noting that there had been evaluations of individual projects, 
the Steering Group that drafted Ireland’s National Drugs 
Strategy 2009–2016 (NDS) observed that ‘there is a need to 
evaluate services in a more comprehensive way that assesses 
not only services being developed and provided under the 
NDS framework, but also closely related services provided 
Evaluating national drugs strategies
The authors argue that classifying drugs according to their 
chemical composition alone, and using this as the basis 
for criminal penalties, policing, prevention, and treatment 
programmes, is not a sufficiently robust approach. The 
risks associated with different substances vary according 
to the drug’s health effects, its safety ratio (i.e. how much 
constitutes a lethal dose), intoxicating effects, general toxicity, 
social ‘dangerousness’ (e.g. aggressive and uncontrolled 
behavior induced by or associated with the use of a drug), 
dependence potential, the environment/context of use, and 
social stigma. The authors conclude, ‘Policies on substance 
use must reflect the social and pharmacological complexities 
of psychoactive substances as well as the relative differences 
among them.’ They point out that using such a rating system 
indicates that legal substances such as tobacco and alcohol 
are at least as dangerous as many illicit substances. 
Having established a conceptual basis for a ‘rational drug 
policy’, which provides a context within which the ‘best 
evidence’ may be more readily recognised, the authors 
provide a critical review of the cumulative scientific evidence 
in five general areas of drug policy: 
prevention ■
supply reduction  ■
treatment and harm reduction ■
criminal sanctions and decriminalisation ■
control of the legal market through prescription   ■
drug regimes.
Acknowledging that policy making should not be solely a 
technocratic endeavour entrusted to scientists, the authors 
came to a consensus that the evidence reviewed in the book 
supported the following conclusions: 
There is no single drug problem, and neither is there a  ■
magic bullet that will solve ‘the drug problem’.
Many policies that affect drug problems are not  ■
considered drug policy, and many specific drug policies 
have large effects outside the drug domain.
Once a drug is made illegal, there is a point beyond  ■
which increases in enforcement and incarceration yield 
little added benefit.
Substantial investments in evidence-based services for  ■
opiate-dependent individuals usually reduce drug-related 
problems.
School, family, and community prevention programmes  ■
have a collectively modest impact, the value of which 
will be appraised differently by different stakeholders.
The drug policy debate is often dominated by four 
false dichotomies (law enforcement vs health services; 
targeting drug use vs damage caused by drug use; 
‘good’ vs ‘bad’ drugs; the interests of heavy drug users vs 
the interests of the rest of society) that can mislead policy 
makers about the range of legitimate options and their 
expected impacts. 
Perverse impacts of drug policy are prevalent. ■
The legal pharmaceutical system can affect the shape of  ■
a country’s drug problem and its range of available drug 
policy options.
 (Brigid Pike)
Babor T, Caulkins J, Edwards G, Fischer B, Foxcroft D, 1. 
Humphreys K et al. (2010) Drug policy and the public 
good. Oxford: Oxford University Press.
Using scientific knowledge to inform drug policy (continued)
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in the broader social inclusion context’ (NDS: para. 6.40). 
Although this observation does not appear to have been 
followed up with an associated action regarding overall 
policy evaluation, the Steering Group did prioritise ‘the 
development of an overall performance management 
framework across all relevant Departments and agencies 
to facilitate the effective assessment and monitoring of 
progress’ (NDS: para. 6.101). Such a framework will help in 
undertaking an evaluation of the NDS at both its mid-term 
(2013) and its expiry (2016).
Policy evaluation was a theme of the recent annual 
conference of the International Society for the Study of Drug 
Policy (ISSDP). Presenters from Luxembourg, the Netherlands 
and Australia reported on recent evaluations of their national 
drugs strategies.2 They made several salient points regarding 
strategy evaluation.
In all three countries, external evaluators were engaged, 
including in one instance an evaluator from another country, 
and sometimes in conjunction with an internal evaluator. 
‘Data triangulation’ was acknowledged as essential to 
validate the conclusions drawn by the evaluators. In Australia 
relevant documentation and datasets were consulted and 
the relevant literature reviewed, stakeholders were consulted, 
and case studies of aspects of policy undertaken. The 
information gathered from all these sources was collated and 
compared and assessed. With a ‘relatively small budget’, the 
evaluators in Luxembourg were restricted to administering a 
questionnaire to stakeholders; holding follow-up interviews 
with survey respondents to develop a SWOT analysis; and 
convening focus groups to recheck information, resolve 
contradictory answers and discuss recommendations/
priorities for the new drug plan.
Finally, the choice of analytical framework to support the 
policy evaluation needs careful thought. The design will vary 
depending on whether it is an action plan or a strategy that is 
being evaluated. The Luxembourg evaluators recommended 
that a ‘programme logic model’ should be used ‘to monitor 
and evaluate the implementation and achievements of the 
[Drug] Action Plan in an effective and transparent way’. While 
the logic may be applied in a simple linear manner – inputs à 
activities à outputs à outcomes – they proposed a matrix form, 
in which the intervention logic, underlying assumptions, and 
objectively verifiable indicators and the means of verification 
for each stage in the model are also evaluated. 
In Australia the National Drug Strategy (NDS) was evaluated 
using a framework with four key components:
evaluate the NDS as a policy framework that informs 1. 
stakeholders in the development of their respective drug-
related policies and programmes;
evaluate the outcomes of programmes under the NDS;2. 
evaluate the roles and workings of the advisory structures 3. 
that inform the development and implementation of the 
NDS; and
monitor the performance of the NDS with regard to 4. 
actual and potential drug issues and drug trends in 
Australia during the period 2006 – 2009.
These components were used to assess the overall effectiveness 
and the efficiency of the NDS, and to identify future needs and 
opportunities for future process or other improvements. 
At the ISSDP conference the consultants who undertook the 
evaluation of the Australian NDS made a case for using an 
additional analytical framework based on policy theories.3 
They suggested that such a framework would provide 
evaluators with insights into the determinants of policy – how 
it is made, the drivers of implementation and its performance 
– which would strengthen the evaluation findings. In a similar 
vein, a recent overview of the development of Ireland’s drug 
strategy between 2000 and 2007 focused on Ireland’s NDS 
as a strategy process – how it was designed, developed and 
managed.4 The objective was to gain insights into how the 
infrastructural elements might have influenced the outcomes 
of the strategy. Arguably, such an analytical lens would 
further strengthen a strategy evaluation. 
(Brigid Pike)
Reitox is the European Information Network on Drugs 1. 
and Drug Addiction, which is co-ordinated by the 
EMCDDA. The network is made up of National Focal 
Points (NFPs) in the 27 EU member states, Norway, the 
European Commission and the candidate countries. 
The EMCDDA holds 1–2-day seminars (academies) for 
network members to provide training on various topics 
relevant to the work of Reitox. Ireland’s NFP is located in 
the Health Research Board.
2. See Trautmann F and Braam R (2009) Evaluation of the 
National Drug Action Plan (2005–2009) of Luxembourg. 
Utrecht: Trimbos-Institut; van Laar M and van Ooyen-
Houben M (2010) Dutch drug policy evaluated. Paper 
presented at 4th annual conference of the ISSDP, Santa 
Monica, California, USA, 15–16 March 2010; McDonald 
D, Cleary G, Miller M, Hsueh-Chih Lai S, Siggins I and 
Bush R (2010) Using theories of policy processes in 
evaluating national drug strategies: the case of the 2009 
evaluation of Australia’s National Drug Strategy. Paper 
presented at 4th annual conference of the ISSDP, Santa 
Monica, California, USA, 15–16 March 2010.
3. The policy theories included the systems model, the 
stages heuristic, the rational/comprehensive model, the 
bounded rationality model, institutional rational choice 
frameworks, the incrementalism model, the punctuated 
equilibrium theory, the multiple streams model and the 
advocacy coalitions model.
4. Pike B (2009) Development of Ireland’s drug strategy 
2000–2007. Overview 8. Dublin: Health Research Board. 
Evaluating national drugs strategies (continued)
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UN body reviews drug policy
The Commission on Narcotic Drugs (CND), the central 
policy-making body within the United Nations system 
dealing with drug-related matters, held its 53rd annual 
session in Vienna between 8 and 12 March 2010. The CND 
monitors the world drug situation, develops strategies on 
international drug control and recommends measures to 
combat the world drug problem.1
Thematic debate
The CND’s annual thematic debate was on the subject of 
‘measures to enhance awareness of the different aspects 
of the world drug problem, including by improving 
understanding of how to tackle the problem’. Key points to 
emerge from the debate included the following: 
There is scientific evidence that drug use, even when •	
occasional, poses serious risks to health.
Long-term and frequent use of illicit drugs has lasting •	
effects on the functioning of the brain, on physical 
and mental health and on behaviour.
Drug use and drug dependence have a range of •	
health-related, social and economic consequences for 
individuals, their families and the community.
Use of drugs by young people is a major concern, as •	
drug use during childhood and adolescence affects 
the healthy development of the brain.
Female and male drug users have different histories •	
and patterns of use. Female drug users are likely to 
have a co-morbid psychiatric disorder and a history of 
physical and sexual abuse and to make non-medical 
use of prescription drugs. The health and social 
consequences of drug abuse for female drug users, 
their families and the community require special 
consideration. Treatment and care services should 
address the special needs of women.
Reliable information on drugs and training for •	
drug prevention should be provided extensively to 
primary health-care workers, teachers, parents, media 
professionals and police officers.
Prevention efforts should address all levels of risk •	
(universal, selective and indicated), such efforts 
to include evidence-based interventions carried 
out in many settings (school, family, community 
and media), and should be tailored for the target 
population groups and be mainstreamed in national 
education and health policies.
Evaluation of interventions to prevent drug use is •	
not only possible but essential, and all drug abuse 
prevention efforts should have strong monitoring and 
evaluation components.
There is an interplay of genetic, neurobiological and •	
environmental factors that make individuals vulnerable 
to using drugs and becoming drug dependent.
Practitioners, policymakers and the general public •	
should be made aware of the changes in brain 
functions that are at the root of compulsive behaviour 
and uncontrollable cravings, and that because of 
these changes drug dependence is most accurately 
classed as a health disorder. 
Given that drug dependence is a health disorder, •	
there is no justification for the stigma, ignorance and 
prejudice that persist and have adverse consequences 
for drug users, their families and the community.
Care for drug addicts should be integrated into •	
mainstream health-care services.
Training of doctors, nurses and social workers •	
should include an understanding of drug addiction 
as a chronic multi-factorial health disorder, and an 
understanding of evidence-based interventions. 
Prevention and treatment strategies should be based •	
on scientific evidence and trials, as is the case with 
other chronic health disorders.
Drug use and drug addiction are separate •	
phenomena: while drug use is largely a function of 
access and availability, drug addiction is largely a 
function of genetic heredity.
Non-governmental organisations often lead the way •	
where no services are available. Their efforts should 
be included in the mainstream provision of health, 
education and social policies, building on the resources 
and the synergies of civil society and the public sector.
Resolutions
On foot of this debate and consideration of reports on 
the world situation with regard to drug abuse and drug 
trafficking, the Commission passed 15 resolutions related 
to, among other issues, strengthening awareness and 
prevention efforts; strengthening international co-operation 
in countering the covert administration of psychoactive 
substances related to sexual assault and other criminal acts; 
strengthening international co-operation in countering 
drug trafficking and related offences; achieving universal 
access to prevention, treatment, care and support for drug 
users and people living with or affected by HIV; measures 
to protect children and young people from drug abuse; 
promoting the sharing of information on the potential abuse 
of and trafficking in synthetic cannabinoid receptor agonists 
(synthetic cannabis); strengthening systems for the control of 
the movement of poppy seeds obtained from illicitly grown 
opium poppy crops; use of poppers as an emerging trend in 
drug abuse in some regions; and strengthening international 
co-operation and regulatory and institutional frameworks for 
the control of substances frequently used in the manufacture 
of narcotic drugs and psychoactive substances.
Ireland and the CND
The CND comprises 53 members elected from among the 
member states of the UN. Ireland is not currently a member of 
the CND, but an Irish delegation attended the 53rd session as 
observers. Delegates included Marita Kinsella (chief pharmacist) 
and Mary O’Reilly of the Department of Health and Children; 
Niall Cullen and John Garry of the Department of Justice and Law 
Reform; Dairearca Ní Néill of the Office of the Minister for Drugs; 
and John Francis Cogan (ambassador) and Niamh Neylon of the 
Permanent Mission to the United Nations, Vienna.2 
(Brigid Pike)
For further information on the 53rd Session of the CND, 1. 
visit www.unodc.org/unodc/en/commissions/CND/ 
For further information on Ireland and UN drug policy, 2. 
see reports in Drugnet Ireland, Issues 8, 18, 22, 27, 30. 
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Legislation
On 11 May the Irish government moved to control the sale 
of psychoactive substances in head shops and on line using 
a two-fold strategy: amendments to the list of controlled 
substances under the Misuse of Drugs Acts 1977 and 
1984, and the newly drafted Criminal Law (Psychoactive 
Substances) Bill 2010 which will prevent the sale of 
substances created to get around existing laws. As of 11 
May, synthetic cannabinoids, benzylpiperazine derivatives 
and six named cathinones are banned substances under the 
Acts, with sentences of up to seven years and/or a fine for 
possession and up to a maximum of life imprisonment for 
supply. The new Bill, when enacted, will make it a criminal 
offence to sell or supply, for human consumption, substances 
which may not be specifically prohibited under existing Acts, 
but which have psychoactive effects. Further amendments 
to existing Acts towards the end of 2010 will regulate other 
head shop products.  
www.dohc.ie/press/releases/2010/20100511.html  
www.justice.ie/en/JELR/Pages/Press_releases
Additional head shop substances
The leading article in the spring issue of Drugnet Ireland (No. 
33) described a range of head shop products; four additional 
substances are described below. 
Fluorotropacocaine
Fluorotropacocaine, a drug derived from the organic 
compound tropane, acts both as a stimulant and as a local 
anaesthetic. It was first reported as a designer drug by the 
European Monitoring Centre for Drugs and Drug Addiction 
in 2008. The drug has been identified in two head shop 
products sold in Ireland: Whack and Stardust. On 9 June 
2010 the Health Service Executive issued an emergency 
warning about ‘Whack’ after 40 people suffering side effects 
of the drug attended emergency departments or general 
practitioners over the preceding 10 days. The majority of 
these individuals were young males in their twenties. They 
lived in different parts of Ireland, with 20 presenting in 
Limerick, Clare or North Tipperary. They reported a range of 
symptoms, such as increased heart rate, increased breathing 
rates and raised blood pressure. The majority experienced 
varying levels of anxiety and at least seven cases experienced 
psychotic episodes. This psychosis was difficult to treat.
Pyrovalerone 
Pyrovalerone is a psychoactive drug with stimulant effects 
that was developed in the late 1960s for the clinical 
treatment of chronic fatigue and as an appetite suppressant 
for weight loss purposes. Because of problems with abuse 
and dependence, it is now less frequently prescribed, but 
there are reports of its continued use in France and South-
East Asia. Its side effects include loss of appetite, anxiety, 
sleep disturbance, and tremors. The user may become 
depressed when use is discontinued. Its use is controlled in 
Ireland, Australia, Britain and the US. Pyrovalerone is closely 
related in structure to a number of other stimulants, such 
as methylenedioxypyrovalerone (MDPV) (banned in Ireland 
under Order of 11 May 2010). Naphyrone (O-2482, NRG-1, 
Energy 1), also known as naphthylpyrovalerone, is a drug 
derived from pyrovalerone that has stimulant effects and  
has been reported as a novel designer drug. It is sold as a 
plant food on line. No safety or toxicity data are available  
on naphyrone.
Aminoindans 
2-Aminoindan is an uncommon short-acting stimulant 
with effects that have been compared to those of 
1-benzylpiperazine or methamphetamine. Little is known 
about its recreational use, but aminoindans are the 
active ingredient in at least one head-shop product, Pink 
Champagne pills, which also contain cola vera and caffeine. 
The pills may cause an increased heart rate and short-term 
insomnia. Online sellers of these products indicate that 
they should not be consumed in combination with alcohol 
or other drugs, particularly anti-anxiety or anti-depressant 
drugs, or by people with any medical condition (in particular, 
heart or liver disease), with mental illness, or who are 
pregnant or breast feeding. 
1,3-dimethylamylamine (DMAA)
1,3-dimethylamylamine or DMAA, also known as 
methylhexaneamine, is a derivative of geranium oil and acts 
as a central nervous system stimulant. Methylhexaneamine 
is registered for use as a nasal decongestant. In combination 
with caffeine and other ingredients, it has been marketed as 
a dietary supplement under trade names such as Geranamine 
and Floradrene. Methylhexaneamine, at extremely low 
concentrations (less than 1%), is a component of geranium 
oil which is approved for use in foods. DMAA is emerging 
as an active ingredient in party pills in New Zealand, where 
the government has indicated its intention to schedule it as 
a restricted substance. Recreational drug users have reported 
adverse effects of DMAA, including headache, nausea, and 
stroke. Online user reports describe a desire to reuse the 
drug, episodes of profuse sweating, and feeling depressed 
and paranoid. Products containing DMAA are available in 
head shops and on line under names such as Iced Diamond, 
Vegas Nights and Blessed. 
Active ingredients identified in products 
Dr Pierce Kavanagh and colleagues (at Trinity College and 
the Drug Treatment Centre Board) identified the active 
ingredients and other constituents in 41 products sold in 
head shops in Dublin and illustrated their results in a poster,1 
reproduced on pages 16-17. This poster is useful for staff 
working in emergency departments and drug treatment 
centres. Eighteen of the products analysed contained 
cathinone derivatives, either in isolation or in combination: 
mephedrone (28% of cathinone products), flephedrone 
(17%), methylone (22%), butylone (17%) and MDPV (22%). 
Dr Kavanagh and his team are analysing other psychoactive 
products to determine their contents and will release the 
results when their research is completed. 
The authors reported that the negative effects of cathinones 
were: dehydration, erectile dysfunction, discolouration of the 
knees attributable to vascular damage (‘blue knees’), cardiac 
arrhythmias, and paranoia. They also said that mephedrone 
had been linked with at least one death in Europe and was 
suspected in other deaths. For further information, email 
id.lab.team@gmail.com
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A joint report by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and European police agency 
Europol1 concludes that ‘the appearance of a large number 
of new unregulated synthetic compounds marketed on 
the Internet [and sold in head shops] as “legal highs” or 
“not for human consumption”, and specifically designed 
to circumvent drug controls, presents a growing challenge 
to current approaches to monitoring, responding to and 
controlling the use of new psychoactive substances’ (p.3). 
The report further states that a distinct feature of the ‘legal 
highs’ phenomenon is the speed at which suppliers target 
‘specific groups of recreational drug users’, offering new 
unregulated alternatives in various guises, ‘from room 
odorisers, through herbal incenses, to bath salts, and 
different patterns of use, including herbal smokable mixes, 
snorting powders, tablets and liquid preparations for oral 
consumption’ (p.7).
The report is the fifth annual report from the two agencies 
on the information exchange, the Early-Warning System 
(EWS) set up by Council decision 2005/387/JHA. The joint 
report provides evidence-based advice to the Council and 
the commission on the need to request a risk assessment 
on a new psychoactive substance. In gathering information 
about new psychoactive substances, the EMCDDA and 
Europol also collaborate with national EWSs, Reitox National 
Focal Points (NFPs), Europol National Units (ENUs), the 
European Medicines Agency (EMA) and, where relevant, the 
World Health Organization (WHO). 
During 2009, 24 new psychoactive substances were officially 
notified for the first time in the EU, the highest number ever 
reported. All substances were synthetic. The emergence 
of new, smokable herbal products laced with synthetic 
cannabinoids (also referred to as ‘spice’) and the growing 
popularity of various synthetic cathinones is seen as the main 
1. Kavanagh P, McNamara S, Angelov D, Mc Dermott S and 
Ryder S (2010) Head shop ‘legal highs’ active constituents 
identification chart (May 2010, pre-ban). A modified version 
of this poster was presented at the All Ireland Joint Schools 
of Pharmacy Research Seminar (March 2010) and at the 
launch of the Trinity Student Medical Journal (April 2010).
Problem drug users’ experiences of head shop products
Carol Murphy and colleagues presented an abstract of their 
survey, displayed a poster titled ‘Head shop bath salts – not 
good clean fun’,1 at the College of Psychiatry of Ireland’s 
spring meeting on 25 March 2010. This survey sought to 
estimate the extent, and describe the experience, of ‘bath 
salts’ use among problem drug users living in a hostel for 
homeless people in Dublin city centre. Nurses or key workers 
administered a questionnaire to a random sample of 20 
clients during December 2009, of whom 17 participated in 
the survey. The researchers found that:
Twelve of those surveyed had tried bath salts on at least  ■
one occasion.
Some of the 12 had tried more than one product; 10  ■
had taken ’Snow’; five had taken ‘Blow’; three had taken 
‘Vanilla Sky’. 
The 12 respondents either snorted or injected the  ■
products.
Ten respondents experienced a rush or euphoria similar  ■
to that of cocaine, ecstasy or crystal methamphetamine.
The products were cheaper than cocaine.  ■
The unwanted side effects were: difficulty in sleeping,  ■
anxiety, agitation, hallucinatory experiences and 
paranoia.
The ‘come down’ was associated with agitation,  ■
depression and paranoia.
1. Murphy C, McCarthy C, Harkin K and Keenan E (2010) 
Head shop bath salts – not good clean fun. Poster 
presentation at the College of Psychiatry spring meeting, 
Dublin, 25 March 2010.
Future research
The National Advisory Committee on Drugs has 
commissioned a review of products sold in head shops and 
other outlets in order to establish what the products contain, 
according to their labelling and on laboratory testing. 
The researchers will investigate availability of reference 
standards to facilitate the analysis of new psychoactive 
substances. They will update an inventory of head shops 
and other outlets (including internet sites) in order to 
assess geographical access to these substances. The users of 
products will be interviewed to determine products used, 
reason for use, expected effects, unexpected effects and 
preferred place or source of purchase. Problem drug users 
will be interviewed to identify specific risks associated with 
their use of these products. Data will be requested from 
hospital emergency departments to determine the negative 
health effects associated with head shop products. The 
research team will examine opportunities for legal and harm 
reduction interventions in Ireland and other countries. For 
further information, contact sscally@nacd.ie
Harm reduction 
Ana Liffey Drug Project has developed a web page on legal 
highs which contains links to published harm reduction 
information. Peer workers at Ana Liffey have produced a 
booklet, Use your head, which provides some guidelines 
on how to minimise harm when taking drugs and how to 
intervene if someone experiences harm caused by drugs. 
www.aldp.ie/index.php?page=legal-highs
(Jean Long)
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cause of ‘significant new developments in the field of  
so-called “designer drugs”’ (p.3).
The report also provides information recently gathered 
by the EMCDDA and Europol about mephedrone 
(4-methylmethcathinone) and about the piperazine 
derivative mCPP, reported as being present in an increasing 
proportion of ecstasy tablets while the availability of MDMA 
on the market appears to be decreasing. Although the reason 
for the apparent decline in MDMA is unclear, the finding 
‘corresponds with the growing number of legal alternatives 
to controlled drugs ... such as mephedrone’ (p.3). 
Mephedrone is sold as a legal high, an alternative to cocaine 
or ecstasy. A number of member states – Ireland, Denmark, 
Germany, Estonia, Romania, Sweden and the UK – as well 
as Croatia and Norway, have recently introduced measures 
to control this substance. The report adds a note of caution 
in this respect: ‘In view of the growing popularity and sales 
of mephedrone, it is important to consider the threat that 
this may pose by creating momentum for an undesirable 
transition, from a mostly online “legal-highs” market, 
originally driven by individual entrepreneurship, to one that 
involves organised crime’ (p.15).
The report concludes with a review of the EWS achievements 
and also identifies some of the challenges which it may 
encounter during the coming years. Such challenges 
include ‘issues that relate to identifying, monitoring and 
understanding the nature of various new substances, which 
increasingly appear on the internet and on the European 
drug markets, as well as the innovation and sophistication of 
their marketing’ (pp.3–4). The EMCDDA is currently piloting 
an ‘internet snapshot’, or ‘multilingual audit of on-line shops 
which are EU-based or dispatch to EU Member States’ (p.7). In 
early 2010, the EMCDDA audited websites in 14 EU languages.
One challenge highlighted in the report relates to the 
importance of forensic and toxicology laboratories having 
access to reference materials (reference substances or seized 
substances), especially if they are to be able to identify new 
synthetic drugs about which limited scientific literature is 
available. Although the EWS has high reporting capabilities, 
the report concludes that ‘despite its speediness and capacity 
to triangulate information from different sources, it has no 
mandate or resources to anticipate and research the future 
market by actively purchasing, synthesising and studying 
new compounds’ (p.15).
(Johnny Connolly)
EMCDDA, Europol (2010) 1. EMCDDA-Europol 2009 
annual report on the implementation of Council Decision 
2005/387/JHA. Lisbon: EMCDDA. Available at  
www.emcdda.europa.eu
The current controversy over so-called ‘head shops’ has 
highlighted the challenge to policy makers of controlling and 
regulating new psychoactive substances which emerge in 
the licit or illicit market.1 For public health reasons, legislators 
may need to bring new substances under control rapidly. A 
recent publication by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) describes the systems 
and procedures available in the European Union, Norway 
and Croatia.2
The comparative study finds that there is a variety of control 
methods available in the different countries, including 
the generic and analogue systems (see below), as well as 
temporary emergency and rapid permanent scheduling 
procedures. The procedures may be effective immediately, 
within several days, or they may need up to a year to 
process. The risk assessment systems that are used to inform 
these procedures also vary widely, with some countries 
having no formal procedures while others include full 
consultation with independent scientists.
The ‘principle of legality’ is a core value which underpins 
the criminal law. This holds that, ‘no one shall be guilty 
of any criminal offence on account of an act or omission 
which did not constitute a criminal offence under national or 
international law at the time when it was committed’.3
Following this principle, controlled psychoactive substances 
need to be clearly identified in any legislation that makes 
their possession or supply a criminal offence. Substances are 
generally defined individually or in tightly defined groups. 
A challenge which can arise, however, is that illicit drug 
producers or traffickers can adjust a chemical compound so 
that it falls outside the definition of a controlled substance, 
or find a new substance that has similar psychoactive effects. 
The challenge then facing policy makers, as highlighted in 
this study, is that they will need to decide ‘if they need to 
bring this new substance under control – and in cases of 
immediate risk to public health, they will need to act quickly’ 
(p.4). Similarly, countries that are parties to the UN drug 
treaties or within the EU may be obliged to add substances 
to their lists within a certain deadline.
This study, an update of a similar study conducted by the 
EMCDDA in 2004,4 looks at the formal systems used by 
member states and by Norway and Croatia to control new 
psychoactive substances (synthetic and otherwise), the 
legal procedures involved and an estimate of the time such 
procedures might take. It also describes the risk assessments 
involved in the various procedures. The methodology used 
for the study involved a questionnaire sent to the ELDD’s 
Legal Correspondents Network and contributions from 
correspondents to the Early-Warning System.
Legal responses to new psychoactive 
substances in Europe
EMCDDA–Europol report on control of new psychoactive  
substances (continued)
drugnet 
Ireland
20
Countries generally follow the individual listing system 
whereby national lists of controlled substances follow the UN 
Conventions, which may also extend the list to a substance’s 
‘isomers, esters, ethers and salts’ (p.5). New substances may 
be added by means of an emergency procedure, which 
is an accelerated procedure whereby new substances are 
controlled for a limited period, or a rapid procedure where 
new controls on new substances are permanent.
In some countries, the individual list system may be 
supplemented by definitions of groups of substances under 
either a generic or an analogue system. A generic system is 
defined in the study as referring to the inclusion within the list 
of individual substances under control of a ‘precise definition 
of a group of substances’ sharing the same compounds or 
molecular structure (p.6). An example of such a definition 
might be ‘any compound structurally derived from fentanyl’ 
by modification in a number of ways, which are then 
described. An analogue system is based on more general 
aspects of similarity in the chemical structure of substances. 
An analogue definition of a compound might be ‘a substance 
– the chemical structure of which is substantially similar to 
the chemical structure of a controlled substance…which has a 
stimulant, depressant, or hallucinogenic effect on the central 
nervous system that is substantially similar to or greater than’ 
the effect of an already controlled substance (p.6).
The report then describes the national systems and 
procedures and the legal practice in each country. In Ireland, 
new substances are controlled both by individual listing and 
by a generic system. In practice, a memorandum is drafted 
and submitted to the relevant government departments 
for comment. A Declaration Order is then issued and the 
Minister for Health and Children sends a draft to the Cabinet. 
Once approved, the Order is signed by the Minister and 
then laid before both houses of the Oireachtas within 21 
days, together with any regulations and exemption orders. 
Notification of the Order is then published in the Irish State 
Gazette (Iris Oifigiúil). The procedure can take approximately 
six weeks, but may take longer if there are drafting delays or 
if the Oireachtas is not in session. This procedure is the same 
regardless of the source of the instructions for placing a new 
substance under control (whether the UN or the EU). The 
study finds that all countries use the individual listing system, 
in addition to which Ireland and the UK use the generic 
system, and Latvia and Norway the analogue system. 
The speed with which changes are introduced can be 
affected by the formalities involved in each jurisdiction. The 
faster procedures are found to be those that require final 
approval of the legal text by one minister, rather than by an 
entire government, or those that shorten the duration of the 
consultations with experts.
The study also considers the risk assessment procedures 
available in different countries. Three questions are addressed 
in this review:
Is the risk assessment procedure part of the general legal  ■
procedures for bringing new substances under control?
Do the harm levels detected by the risk assessment  ■
influence the speed of the legal procedure?
Is the risk assessment performed by experts within the  ■
public administration or by independent scientific experts?
In Ireland, although there is no legally-based requirement 
for risk assessment, the Early Warning and Emerging Trends 
sub-committee of the National Advisory Committee on 
Drugs (NACD) was established to carry out risk assessments, 
as well as to contribute to risk assessments carried out at the 
European level. To date, no instances of  
risk assessment outside UN/EU proposed substances have 
been reported. 
(Johnny Connolly) 
Long J (2010) Conference on psychoactive drugs sold in 1. 
head shops and on line. Drugnet Ireland (33): 1–3. 
Hughes B and Blidaru T (2009) 2. Legal responses to new 
psychoactive substances in Europe. Lisbon: European Legal 
Database on Drugs. http://eldd.emcdda.europa.eu/
European Convention on Human Rights, Art. 7(1) 3. 
EMCDDA (2004) 4. Legal responses to new synthetic drugs 
2000–2004. Lisbon: European Legal Database on Drugs. 
http://eldd.emcdda.europa.eu
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The Pompidou Group (PG) consists of 35 member states, 
including Ireland, which work together to develop drug 
policies to combat illicit trafficking in drugs and drug abuse. 
The PG was formed at the instigation of the French President 
Georges Pompidou in 1971, and incorporated into the 
Council of Europe in 1980.1
In celebrating its first 30 years, the PG states that its unique 
contribution has been to provide the only forum of open 
discussion on the drugs issue that is not constrained by 
ideological or political considerations. Because of this, the 
PG has been able to develop and promote effective drug-
related policies, i.e. policies that have actually reduced supply 
and demand. Among its achievements over the past three 
decades, the PG lists the following:
The concepts of monitoring trans-national drug abuse 1. 
and indicator development were introduced by the PG, 
and then taken over by the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA). Methods to 
measure the use of alcohol, tobacco and drugs were 
developed by the PG, and the European School Survey 
Project on Alcohol and other Drugs (ESPAD) is now an 
independent programme that serves governments in 51 
countries as the principal data source in drug-use trends.
Control of drug trafficking in civil aviation through 2. 
co-operation between customs and law enforcement 
agencies across member states has been supported 
by the PG’s Airports Group, which regularly updates 
member states on the modus operandi of drug traffickers 
in civil aviation.
The PG has sought to develop effective approaches to 3. 
drug prevention. It compiled the Prevention Handbook for 
policy managers and practitioners, and school-based life-
skills training modules developed by the PG are widely 
used in Europe.
Effective involvement of civil society in reducing drug 4. 
use and the associated negative social and health 
consequences owes much to two PG initiatives, the 
European Consultative Forum and the European Drug 
Prevention Prize, which have engaged young people, 
particularly those in at-risk groups, in preventing drug 
use among their peers.
Targeted drug treatment policies leading to the re-5. 
integration of drug users into society have been the result 
of the PG’s integrated approach to linking policy with 
practice and research. Achievements include treatment as 
an alternative to prison, treatment standards for young 
drug users and women, drug addiction treatment in 
prisons, and principles and guidelines for reducing drug-
related HIV/AIDS infections.
The PG was the first body to develop and promote 6. 
policies for effectively dealing with open drug scenes 
in cities. The significant reduction of open drug scenes 
in Europe over the past 15 years can be attributed to a 
great extent to the PG’s work. 
The PG is the only body to address ethical and human 7. 
rights issues related to drug control policies. Attention 
to such issues has been identified by the International 
Narcotics Control Bureau (INCB) as key to effective 
implementation of drug policies. The PG has already 
provided member states with guidance on the conduct 
of drug screening. 
The MedNET network, which is supported by the PG, has 8. 
made it possible to measure for the first time the scope 
of the drug problem in Algeria, Morocco and Lebanon 
and has informed the development of drug strategies in 
these countries based on risk-reduction policies. Under 
MedNet the PG has organised training for medical staff in 
drug addiction treatment, including opiate substitution 
treatment taking into account the right to health of the 
drug user. 
Looking to the future, the PG has announced its intention to 
concentrate on three main themes:
1. involving target groups in developing, implementing and 
reviewing drug demand reduction policies,
2. combining policy with research and practice in order to 
overcome barriers to policy implementation and increase 
efficiency and effectiveness, and 
3. bringing the human rights dimension to the forefront in 
tackling drug problems, and in particular, 
the human rights and ethical aspects concerning •	
vaccinations against cocaine use 
human rights as a key factor to better balance •	
repression and prevention 
the ethics of using developments in neuro-science to •	
influence behaviour 
the crucial role and added value of human rights in •	
drug treatment and rehabilitation.
(Brigid Pike)
The Social Inclusion Unit of the Department of Health 1. 
and Children is Ireland’s Permanent Correspondent to 
the Pompidou Group. For further information on the 
Pompidou Group, visit www.coe.int/t/dg3/pompidou/
AboutUs/default_en.asp 
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The Inchicore Community Drug Team (ICDT) launched 
its strategic plan for 2010–2012, Taking stock and moving 
forward, in April 2010.1 The plan was officially launched by 
Mr Pat Carey, Minister for Community Equality and Gaeltacht 
Affairs. 
The vision set out in the strategic plan is ‘that all those living 
with drug addiction in Inchicore will have access to a holistic 
addiction service locally’. 
Six strategic goals were identified for the three-year period of 
the plan:
To provide a safe environment where people affected by  ■
drug addiction can explore in a non-judgemental way 
the issues affecting their lives. 
To promote opportunities for individuals to move out of  ■
the cycle of drug addiction. 
To develop opportunities for children and young people  ■
to reach their full potential. 
To identify gaps in service provision and initiate local  ■
responses. 
To promote a better understanding of how the drug  ■
problem affects the local area, and to increase the 
community awareness of drug issues. 
To develop ICDT structures, roles and responsibilities in  ■
accordance with the strategic plan. 
The plan also outlines a number of actions to be undertaken 
by ICDT:
Develop a minimum service level for those on low- ■
threshold programmes. 
Develop a needle exchange in Inchicore in partnership  ■
with the Canal Communities Local Drugs Task Force and 
the Health Service Executive. 
Develop holistic interventions in response to drug-use  ■
trends among service users. 
Develop programmes to meet the needs of children aged  ■
10–14 years who have outgrown the Children’s Project.
Develop an inter-agency youth programme targeted at  ■
those involved in drug dealing.
Establish a working group and develop a local strategy in  ■
response to benzodiazepine dependency.
Establish an inter-agency response to meet the mental  ■
health needs of service users. 
Develop a family welfare forum in conjunction with local  ■
agencies, with the aim of improving the quality of life of 
children living in vulnerable families. 
Develop the ICDT website and publish a regular newsletter.  ■
(Anne Marie Carew)
Inchicore Community Drug Team (2010) 1. Taking stock and 
moving forward: strategic planning document 2010–2012. 
Dublin: Inchicore Community Drug Team. 
ICDT launches three-year strategic plan 
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Attending the launch of the ICDT Strategic Plan, (l to r) Terence Murphy, Minister Pat Carey and Kiera Keogh 
(photo courtesy ICDT)
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Guidelines for peer-led family  
support groups
The Family Support Network (FSN) launched its long-
awaited good practice guidelines for peer-led family support 
groups1 in Dublin Castle on 7 April 2010. The audience 
was welcomed by FSN chairman Mr Tony Hickey, and the 
guidelines were formally launched by Mr Eamonn Quinn of 
the Quinn Family Trust, who part-funded the project. Ms 
Sadie Grace, co-ordinator of FSN, gave a brief overview of 
the guidelines. 
Geraldine Hanlon, Marian Davitt, Tiffany Bourke, Gwen 
McKenna, Brendan Doyle, Breda Fell and Bernie Howard, all 
members of family support groups, spoke about their own 
experiences, about the benefits of such groups, and about 
issues such as starting up, confidentially and respite care. 
Minister Pat Carey, Department of Community, Equality and 
Gaeltacht Affairs, also spoke at the launch. 
Developed after consultation with a wide range of interested 
stakeholders, the guidelines are intended to be used by 
all members of family support groups, with the following 
objectives:
To assist family support groups to develop good practice  ■
in all areas of the work of the group.
To identify training and other resources required to  ■
support good practice.
To ensure consistency in the practice of family support  ■
groups throughout the country.
To provide a basis for affiliation to the FSN. ■
The document has six sections:
Introduction1.  includes items on who the guidelines are 
for and how best to use them;
Starting a peer-led family support group2.  includes 
items on the composition of groups, code of ethics and 
practice advice for convening meetings;
Providing support in a group3.  examines aspects of 
confidentiality, identifying the needs of members, and 
group development;
Facilitation4.  outlines the role and attributes of a good 
facilitator;
Seeking external support5.  deals with identifying 
information, self-development and training needs of  
a group; 
Setting up a family support network6.  outlines the 
benefits and issues involved in setting up a network of 
support groups.
Each section concludes with reflective exercises and ‘top 
tips’, which are also available in the form of a separate 
resource pack.
As well as being very comprehensive, this document clearly 
draws on a wealth of personal experience among the families 
themselves and those working with them. It is intended that 
the guidelines will be reviewed and updated over time.
(Suzi Lyons)
Family Support Network (2010) 1. Good practice  
guidelines for peer-led family support groups. Dublin: 
Family Support Network.
Mr Eamonn Quinn of the Quinn Family Trust formally launched the FSN guidelines (photo courtesy FSN)
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Table 2 Drink driving – awareness of risk and support  
for countermeasures
Ireland
%
EU27
%
Knows the relevant legal BAC limit 8 27
Believes it safe to drive after 
consuming more than two drinks 4 14
Random police checks would  
reduce people’s alcohol consumption  
before driving 93 83
BAC levels for young and novice 
drivers should be decreased to 0.2g/l 82 73
The survey also investigated opinions regarding the 
responsibility for and prevention of alcohol-related harm. In 
Ireland, 53% consider individuals to be mainly responsible for 
protecting themselves from alcohol-related harm (Table 3). 
There is strong evidence that alcohol is price sensitive, with 
consumption increasing as price decreases and vice versa.4 
Young people and heavy drinkers are the two groups of 
people who are most likely to be affected by price changes. 
One third (31%) of Irish respondents believe that young and 
heavy drinkers would buy less alcohol if prices increased by 
25%. One third state that they themselves would buy less 
alcohol if the price increased, and 18% would buy more 
alcohol if the price decreased. This demonstrates that there 
is a lack of awareness among Irish people of what policies are 
effective in reducing alcohol consumption. 
Attitudes towards alcohol: Special 
Eurobarometer
Europe is the region with the highest per capita 
consumption of alcohol in the world. In the European 
Union (EU), harmful and hazardous alcohol consumption is 
the third largest risk factor for ill health, and is responsible 
for 195,000 deaths each year. The economic cost to the 
EU each year is estimated at €125 billion.1 Against this 
backdrop, the European Commission recently commissioned 
a survey of respondents in each of the 27 member states, 
with the aim of analysing EU citizens’ alcohol consumption 
patterns, their awareness of the adverse health and social 
effects, and opinions regarding policy options to reduce 
alcohol-related harm.2 Fieldwork took place in October 2009 
and respondents were interviewed face-to-face in their own 
homes. In Ireland, 1,008 respondents were interviewed. A 
similar survey was conducted in 2006.3
Main findings
The majority of the EU population drink alcohol, with 76% 
reporting that they had consumed alcohol in the year prior 
to the survey. Although Irish people drink on fewer occasions, 
they are the most likely of EU citizens to consume more 
drinks on a drinking occasion and to binge drink (defined as 
consuming at least five drinks on a singe drinking occasion) 
(Table 1). Just 34% of Irish respondents consume two 
drinks or less per drinking occasion, compared to 69% of 
Europeans. The survey also found men more likely to engage 
in weekly binge drinking than women (36% vs. 20%). 
Table 1 Selected drinking patterns in Ireland and EU27
Ireland
%
EU27
%
Abstainer 24 24
Drinks 4+ times per week 7 21
Drinks 5+ drinks per drinking occasion 26 10
Weekly binge drinker 44 29
Irish respondents reported high levels of support for 
drink-driving countermeasures (Table 2). Although Irish 
respondents were largely uninformed about the legal blood 
alcohol concentration (BAC) limit, just 4% stated that it 
would be safe to drive after consuming more than two 
drinks, compared to 14% of Europeans. Among Irish people 
there is widespread support for reducing the permitted 
BAC for young and novice drivers. The level of support for 
drink-driving countermeasures among Irish people may be 
attributed to the introduction of random breath testing in 
2006, which has been credited with reducing road deaths 
and the work of the Road Safety Authority.
Table 3 Support for public policies on alcohol
Ireland
%
EU27
%
Individuals are responsible enough 
to protect themselves from alcohol-
related harm 53 53
Young and heavy drinkers would buy 
less alcohol if prices increased by 25% 31 26
Respondent would buy less alcohol if 
prices increased by 25% 34 35
Respondent would buy more alcohol if 
prices decreased by 25% 18 14
All European countries are strongly in favour of prohibiting 
the selling and serving of alcohol to people under the age of 
18. There is strong support for measures that restrict young 
peoples’ exposure to alcohol, with 81% of Irish respondents 
in favour of the banning of alcohol advertising that targets 
young people (Table 4). Not surprisingly perhaps, young 
people aged 15–24 years were least likely to favour controls 
that tighten regulations concerning their age group. There is 
broad support for putting warning labels on alcohol bottles 
in order to inform pregnant women and drivers of the 
dangers associated with drinking alcohol, with 86% of Irish 
respondents in favour of such an initiative. 
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Table 4 Support for measures to protect young people 
and pregnant women
Ireland
%
EU27
%
Selling and serving of alcohol to 
under-18s should be banned 91 89
Alcohol advertising targeting young 
people should be banned 81 77
Alcohol containers should carry labels 
warning pregnant women and drivers 
of the dangers of alcohol 86 79
Conclusion
While this survey shows that the proportion of Irish 
respondents reporting weekly binge drinking has decreased 
since 2006, drinking patterns in Ireland are still problematic. 
More encouragingly, there is widespread support for 
drink-driving countermeasures and for measures aimed at 
protecting young people from premature exposure to alcohol. 
(Deirdre Mongan)
Attitudes towards alcohol: Special Eurobarometer (continued)
Anderson P and Baumberg B (2006) 1. Alcohol in Europe: 
a public health perspective. London: Institute of Alcohol 
Studies. Available at http://ec.europa.eu/health-eu/doc/
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TNS Opinion & Social (2010) 2. EU citizens’ attitudes 
towards alcohol. Special Eurobarometer 331. Brussels: 
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WHO Regional Office for Europe (2009) 4. Evidence for 
the effectiveness and cost-effectiveness of interventions to 
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Minister Pat Carey of the Department of Community, Equality 
and Rural Affairs launched the report of a study on drug and 
alcohol use in the Midland region on 7 May.1 Commissioned 
by the Midland Regional Drugs Task Force, the aim of the 
study was to establish an evidence base for drug-related 
issues in the Midland region to inform the development of 
appropriate response strategies. The study used information 
from several different sources, including national drug 
prevalence data, the National Drug Treatment Reporting 
System (NDTRS) and the Central Statistics Office. Interviews 
and focus groups were also conducted with key informants 
(e.g. service providers, drug users, family members) in four 
selected communities in the region. 
Many of the issues identified were common to all four 
communities and could be generalised to the whole of the 
Midland region. The report highlights these issues and makes 
some key recommendations:
Expand and improve existing addiction services to cope 
with increasing numbers of individuals requiring treatment 
for drug and alcohol problems.
Facilitate access to addiction services ■  by reducing 
waiting lists and by addressing issues of distance and 
adequate transportation when locating new or expanded 
services.
Expand harm reduction programmes ■  and set up 
additional ones as needed. 
Improve access to methadone treatment ■  and reduce 
waiting lists by increasing the number of general 
practitioners providing methadone in the community 
and by expanding and improving existing services. 
Improve access to detoxification, rehabilitation and  ■
aftercare services in line with the recommendations 
of the report of the HSE Working Group on Residential 
Treatment and Rehabilitation.2
Report on drug and alcohol use in the 
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Enhancing the quality and effectiveness of services for 
drug users
Article by Roland Simon in Drugnet Europe No. 70,  
April–June 2010 
Enhancing the quality and effectiveness of drug prevention, 
treatment, harm reduction and rehabilitation interventions 
is one of the key objectives of the current EU drugs action 
plan (2009–12). In order to translate this goal into concrete 
action, the plan foresees developing, implementing and 
exchanging quality standards and guidelines for services 
and interventions in these areas. The European Commission 
(DG–JLS) is supporting an EU-funded research project to 
develop ‘minimum quality standards and benchmarks’ in the 
four fields. The project will take stock of standards already 
existing in Europe and develop a mechanism of consensus-
building between the EU Member States.
The EMCDDA has been working in this domain for over 
a decade. In 2008, it launched its Best Practice portal, 
designed to help those working in these fields take evidence-
based decisions when planning interventions. More recently 
it has conducted a review of national treatment guidelines1 
and is currently collaborating in another EU-funded research 
project to produce evidence-based drug prevention 
standards for use in the EU.2 In the light of its experience, 
the EMCDDA will work closely with the Commission on this 
initiative, participating in the project steering group and 
offering technical support as required.
1. A Selected Issue report on the implementation of the 
treatment guidelines will be published in 2011. 
2. www.emcdda.europa.eu/publications/drugnet/
online/2010/69/article8
New EMCDDA monograph focuses on harm reduction
Article in Drugnet Europe No. 70, April–June 2010
EMCDDA Monograph No 10, entitled Harm reduction: 
evidence, impacts and challenges,1 was released in April. In 16 
chapters authored by over 50 European and international 
experts, the monograph provides a comprehensive overview 
of the harm reduction field. Part I looks at the emergence of 
harm reduction approaches and their diffusion as part of the 
new public health movement of the mid-1980s. It explores 
the concept from several perspectives (e.g. international 
organisations, academic researchers and drug users). Part II is 
dedicated to current evidence and impacts of harm reduction 
and illustrates how the concept has broadened to cover a wide 
range of behaviours and harms, including those related to 
alcohol, tobacco and recreational drug use. Part III addresses 
challenges and innovations and the requirement to integrate 
and match interventions to individual and social needs.
Available at www.emcdda.europa.eu/publications/1. 
monographs/harm-reduction
Drugnet Europe is the quarterly newsletter of the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
available at www.emcdda.europa.eu.
If you would like a hard copy of the current or future issues, 
please contact: 
Health Research Board  
Knockmaun House  
42–47 Lower Mount Street  
Dublin 2 
Tel: 01 2345 127 
Email: drugnet@hrb.ie
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Address problem alcohol use in a more  ■
comprehensive way, not only by providing adequate 
treatment facilities but also by adopting broader 
strategies, including education, increased taxation and 
regulation. 
Address the lack of adequate services for under-18s ■  
by providing adolescent-specific services offering a 
complete, integrated range of services, in line with the 
recommendations of the Department of Health and 
Children.3 
Improve drug awareness education ■  for all age groups. 
Reduce drug-related deaths ■  by using strategies such as 
providing education in overdose prevention and training 
in basic life support.
Provide social reintegration services to ■  recovering and 
former drug users through accommodation, re-training 
and employment supports.
Evidence of drug crime ■ , such as drug markets, was 
found in the region. A partnership approach involving 
all the key stakeholders is one strategy to tackle this 
problem.
(Suzi Lyons)
Lyons S, Robinson J, Carew AM, Gibney S, Connolly J, 1. 
Long J et al. (2010) Close to home: a study on the misuse 
of drugs and alcohol in the Midland region. Tullamore: 
Midland Regional Drugs Task Force.
O’Gorman A and Corrigan D (2008) 2. Report of the HSE 
working group on residential treatment and rehabilitation 
(substance users). Dublin: HSE.
Working Group on treatment of under 18 year olds (2005)3.  
Report of the working group on treatment of under 18 year 
olds presenting to treatment services with serious drug 
problems. Dublin: Department of Health and Children.
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The National Documentation Centre is piloting a course in 
evidence-based practice in drug prevention and education 
work. The course, which lasts for 12 weeks, was launched 
in early March. The 12 participants on the course are 
from a variety of backgrounds, but most work in the drug 
prevention and education field. The aim of the course is to 
teach the participants a range of information-literacy skills 
which will help them understand how evidence in their 
field is produced, how this evidence can be found and how 
research-based knowledge can be used to shape policy and 
bring about better health outcomes.
The course participants bring to it considerable knowledge 
of their own specialist field and experience of planning 
and delivering educational and instructional programmes. 
They already have some research and information-retrieval 
skills and some understanding of the role of evidence in the 
formation of policy in this area. The course draws heavily  
on the participants’ conceptual, technical and  
communication abilities. 
The course comprises seven modules covering the following 
topics: the policy context; the research infrastructure; the 
evidence for drug prevention interventions; evidence-based 
medicine; searching the scientific literature; critical appraisal; 
and data sources.
A successful outcome will depend on participants’ capacity 
to make logical links between the production of evidence, 
finding evidence, and the role of evidence in policy 
development. It is intended that the outcome will be of 
direct benefit to the participants’ daily practice and will 
enable them to contribute to the adoption of evidence-based 
approaches to policy decisions. A problem-based learning 
approach encourages the type of enquiry, discourse and 
collaborative effort which will be needed to make full use of 
the newly acquired information-literacy skills. 
Assessment is based on performance in a group presentation, 
and on participation in online discussion throughout the 
course. The presentation is the group’s response to a 
problem they identified at the beginning of the course. 
There are three face-to-face sessions, but most of the 
course is delivered online. Content and learning activities 
are supported by the Moodle course management system. 
The decision to deliver the course online was based on the 
following considerations:
The participants work and live in diverse locations and a  ■
distance learning element will provide the flexibility for 
those with limited opportunity to travel.
As it is an information literacy course, it will require the  ■
participants to engage with online resources and develop 
an awareness of the potential of the internet for research, 
communication and collaborative working.
The emergence of the evidence-based medicine  ■
movement is closely linked to the rapid development 
of electronic scientific publishing. An understanding of 
EBM will require an awareness of the virtual environment 
which has fostered it.
Following completion of the pilot course, an evaluation 
report will be prepared and submitted to an appropriate 
accreditation body. The course will be repeated in the future, 
when details will be advertised in Drugnet Ireland and on the 
NDC website at www.drugsandalcohol.ie.
(Brian Galvin)
Online course in evidence-based 
practice for drug prevention workers
 
 
Participants on the NDC's elearning course in 
evidence-based drug prevention practice  
(photo JJ Berkeley)
Brian Galvin and Louise Farragher (NDC) with Paul 
Gormley and Catherine Bruen (Vista eLearning 
Consultancy) during the first session of the new 
course (photo JJ Berkeley)
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On 19 January 2010 the Revenue Cutter Service was the 
subject of a response by Minister for Finance, Brian Lenihan 
TD, to a Parliamentary Question (PQ). He stated that the 
Revenue Commissioners have two cutters involved in the 
patrol and monitoring of the State’s maritime jurisdiction and 
adjacent waters. The aim is to prevent, detect, intercept and 
seize prohibited and restricted goods (including narcotics) 
smuggled into or out of the State/EU. The cutters also co-
operate with other national enforcement agencies and with 
international customs agencies in combating drugs trafficking 
by sea. www.oireachtas.ie 
On 2 February 2010 prescription drugs were the subject 
of a PQ. Minister for Health and Children, Mary Harney TD, 
stated: ‘Certain prescription medicines have been declared 
controlled drugs in accordance with the Misuse of Drugs 
Act 1977 — for example, products containing morphine, 
methadone, flunitrazepam and possession of these products, 
in contravention of the Act, is an offence. Under the Misuse 
of Drugs (Exemption) Order 1988, it is not an offence for a 
person to possess prescription medicines containing certain 
benzodiazepines.’ www.oireachtas.ie
On 2 February 2010 Policing Priorities 2010 were announced 
by the Minister for Justice, Equality and Law Reform, Dermot 
Ahern TD. In addition to the continuing fight against gangland 
crime (including targeting drug trafficking and low-level 
street dealing), the Minister has prioritised security; policing 
communities (including adopting a low tolerance to alcohol- 
and drug-related anti-social behaviour and youth crime); 
customer service; roads policing and human trafficking. The 
policing priorities set by the Minister are reflected in the Garda 
Síochána Policing Plan for 2010. www.garda.ie 
On 25 February 2010, at the Irish Youth Justice Service’s 2nd 
biennial conference, Barry Andrews TD, Minister for Children 
and Youth Affairs, launched the online learning community 
YJforum for those working on Garda Youth Diversion Projects. 
This web-based forum provides an opportunity for practitioners 
working in the youth justice system to share their experiences 
and work together to strengthen the system. Copies of 
the presentations made at the conference, together with a 
Conference Report, are available on the IYJS website. www.iyjs.ie 
On 18 February 2010 the Dial to Stop Drug Dealing campaign 
was the subject of a PQ. Minister of State at the Department 
of Community, Rural and Gaeltacht Affairs, John Curran TD, 
stated: ‘Due to the success of the campaign, I have again made 
funding available in 2010 to keep the phone line open. Over the 
coming months, I will be reviewing various options for further 
promotional campaigns, perhaps through a more centralised 
approach or through potential linkages with other campaigns 
and fora.’ www.oireachtas.ie
On 23 February 2010 drug policy in the European Union 
was the subject of a public hearing, when approximately 40 
representatives of European civil society organisations from 15 
countries came together to formulate their recommendations 
to members of the European Parliament, the European 
Commission and the European Council on the approach that 
the European Union should take regarding criminalised drugs. 
The main issue on the agenda was the Report on Global Illicit 
Drugs Markets 1998–2007, that was financed by the European 
Commission in 2008.1 The hearing resulted in recommendations 
to the EU institutions, including calls for (1) the organisation of 
a EU Summit to discuss innovative drug strategies not based on 
prohibition, with delegations of national and local authorities, 
parliamentarians and civil society organisations present, and (2) 
the strengthening of the ‘harm reduction’ approach, promoting 
drug policies that respect human rights, individual freedoms and 
social cohesion. www.encod.org 
On 25 February 2010 an Internal Security Strategy for 
the European Union (5842/2/10) was approved by the 
Council for Justice and Home Affairs. The strategy lays out 
a European security model, which integrates action on law 
enforcement and judicial co-operation, border management 
and civil protection, with due respect for shared European 
values, such as fundamental rights. It identifies the main 
threats and challenges the EU is facing, including organised 
crime, cyber-crime, and drug and arms trafficking. The 
Council also adopted the decision to set up the Standing 
Committee on Operational Cooperation on Internal 
Security (COSI) (16515/09 and 5949/10). COSI’s co-
ordination role will concern, among other things, police and 
customs co-operation, external border protection and judicial 
co-operation in criminal matters relevant to operational 
co-operation in the field of internal security. The committee 
shall regularly report on its activities to the Council which, 
in return, shall keep the European Parliament and national 
parliaments informed. COSI will also be responsible for 
evaluating the general direction and efficiency of operational 
co-operation. www.consilium.europa.eu 
On 9 March 2010 Cosc – the National Office for the 
Prevention of Domestic, Sexual and Gender-based 
Violence published a national strategy on domestic, sexual 
and gender-based violence for 2010–2014.  The report 
states: ‘Although the relationship between substance use 
and domestic and sexual violence is complex, there are clear 
indications that alcohol use, particularly heavy drinking and 
binge drinking, not only complicates the extent and nature of 
violence against women, particularly among intimate partners, 
it also increases the likelihood of re-assault and reduces the 
likelihood of perpetrators of domestic violence completing 
treatment.’ www.cosc.ie 
On 23 March 2010 the Social, Personal and Health 
Education (SPHE) programme was the subject of a PQ. 
Minister for Education and Science, Batt O’Keeffe TD, stated: 
‘Although the Walk Tall Support Service will no longer exist 
in its current guise, it is my intention that the support for 
substance misuse prevention be further integrated into SPHE 
support. It is widely acknowledged that while a strand of SPHE 
can be taught in isolation, it should be linked to each of the 
other strands of the SPHE curriculum in order to be at its most 
effective.’ www.oireachtas.ie
On 31 March 2010 Ireland’s proposed National Substance 
Misuse Strategy was mentioned by the Minister for Tourism, 
Culture and Sport, Mary Hanafin TD, during Question Time in 
Dáil Éireann: ‘The Department [of Tourism, Culture and Sport] 
is also represented on a steering group developing proposals 
for an overall national substance misuse strategy. The group 
is chaired by the Department of Health and Children and the 
office of the Minister of State with responsibility for drugs. 
Part of the strategy will relate to preventative measures and 
the subjects of sports and arts activities are expected to be 
included within this framework.’ www.oireachtas.ie
(Compiled by Brigid Pike)
For a summary of the report, see Connolly J and Donovan 1. 
AM (2009) A report on global illicit drug markets. Drugnet 
Ireland, (30): 23–24. 
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Journal articles
The following abstracts are cited from recently published 
articles relating to the drugs situation in Ireland.
Head shop compound abuse amongst attendees of the 
Drug Treatment Centre Board 
MacNamara S, Stokes S and Coleman N 
Irish Medical Journal 2010; 103 (5) 
www.drugsandalcohol.ie/13185
The use of ’Head shop‘ compounds has received much 
media attention lately. There is very little research in the 
current literature with regard to the extent of the usage 
of these substances amongst the drug using population in 
Ireland. We conducted a study to examine the extent of 
the usage of Mephedrone, Methylone and BZP amongst 
attendees of Methadone maintenance programs at the 
DTCB. Two hundred and nine samples in total were tested. 
The results showed significant usage of these compounds 
amongst this cohort of drug users, with 29 (13.9%) of 
samples tested being positive for Mephedrone, 7 (3.3%) 
positive for Methylone and 1 (0.5%) positive for BZP.
Factors predicting completion in a cohort of opiate users 
entering a detoxification programme 
Mullen L, Keenan E, Barry J, Long J, Mulholland D, Grogan L 
and Delargy I 
Irish Journal of Medical Science (In press, published online 21 
February 2010) 
www.drugsandalcohol.ie/12940
Aim; To determine the outcome and factors influencing 
outcome among a cohort of drug users commencing 
detoxification from opiate use.  
Methods: National cohort study of randomly selected opiate 
users commencing methadone detoxification treatment in 
1999, 2001 and 2003 (n=327).  
Results: One quarter 62 (25.6%) of opiate users had a 
successful detoxification within the three-month study 
criteria. Receiving some inpatient treatment as part of 
detoxification programme resulted in completion by 56.3% 
drug users compared to treatment at outpatient only (21%). 
The factors independently influencing detoxification are as 
follows: having some inpatient treatment (AOR 5.9, 2.63–
13.64) and never having injected (AOR 2.25, 1.20–4.25).  
An additional 31 (9%) opiate users had a detoxification 
between 3 months and 1 year and 27 (8%) moved into 
methadone maintenance.  
Conclusions: This study finds that having some inpatient 
treatment increases the likelihood of a successful opiate 
detoxification within three months. Offering an opiate 
detoxification early in a drug using career, pre-injecting drug 
use, should be considered for suitable and motivated patients.
Sex, drugs and STDs: preliminary findings from the 
Belfast Youth Development Study
McAloney K, McCrystal P, and Percy A 
Drugs: education, prevention and policy (In press, published 
online 2 April 2010) 
www.drugsandalcohol.ie/13061 
Young people’s participation in sexual risk behaviours is 
commonly linked with participation in a range of other risky 
behaviours, and in particular with substance use behaviours.
This cross-sectional analysis of the sixth sweep of the Belfast 
Youth Development Study aimed to examine associations 
between substance use and sexual activity and related 
risks among 17–19-year olds in Northern Ireland. Being 
sexual activity and participating in sexual risk behaviours 
was associated with the use of a range of licit and illicit 
substances particularly alcohol and ecstasy. Additionally, 
females were more likely to have been tested for a sexually 
transmitted disease (STD).
The findings add to the existing research body suggesting 
that substance misuse and sexual risk behaviours tend to 
co-occur in adolescence, and highlight a need to develop 
appropriate interventions and initiatives for school-aged 
young people.
Emergencies related to cocaine use: a European 
multicentre study of expert interviews
de Millas W, Haasen C, Reimer J, Eiroa-Orosa, FJ and  
Schaefer I 
European Journal of Emergency Medicine 2010; 17 (1) 33–6
Illicit drug use can lead to acute reverse reactions leading 
to admission to emergency departments. Cocaine-related 
emergencies have been monitored in the USA, but not in 
Europe so far.
The study investigates patterns of cocaine emergencies in 
eight European cities in a multicentre cross-sectional study 
conducted in Barcelona, Budapest, Dublin, Hamburg, 
London, Rome, Vienna and Zurich. The reported frequency 
differs from city to city, with some emergency centres having 
less than one case per half year, and some centres having 
more than one case per month. Patterns of complaints 
among cocaine users are associated with the psychomotor-
stimulant or cardiovascular effects of cocaine. Urine screens 
and referrals to the addiction services are infrequent.
A closer link between emergency departments and addiction 
services would help in guiding problematic drug users 
towards appropriate treatment at an earlier stage in the 
addiction process.
Prevalence of psoriasis in patients with alcoholic  
liver disease
Tobin AM, Higgins EM, Norris S and Kirby B 
Clinical and Experimental Dermatology 2009; 34(6): 698–701
Background: Excessive alcohol use has been implicated as 
a risk factor in the development of psoriasis, particularly 
in men. Despite this, little is known of the incidence or 
prevalence of psoriasis in patients who misuse alcohol. 
Objective: To assess the prevalence of psoriasis in patients 
with alcoholic liver disease. Methods: In total, 100 patients 
with proven alcoholic liver disease were surveyed for a 
history of psoriasis and a full skin examination was performed 
if relevant.  
Results: Of the 100 patients, 15 reported a history of psoriasis 
and another 8 had evidence of current activity, suggesting a 
prevalence (past or present) of 15% in this group of patients. 
Conclusion: It would appear that the prevalence of psoriasis 
in patients who misuse alcohol is much higher than the 
1–3% variously quoted in the general population.
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(Compiled by Joan Moore; email jmoore@hrb.ie)
June
30 June 2010
Sharps – Best practice in needle exchange and  
harm reduction
Venue: 28 Portland Place, London, W1B 1DE 
Organised by / Contact: Royal Society for Public Health, 
Jennifer Tatman 
Email: jtatman@rsph.org.uk; tel: 020 3177 1614  
www.rsph.org.uk
Information: This conference will allow best practice and 
new initiatives in the provision of needle exchange services 
to be publicised, with the practitioners responsible available 
for questions and comments. Speakers will include experts 
in the area of needle exchange and drug misuse, with 
speakers from the Joseph Rowntree Foundation, the National 
Treatment Agency and the NHS. The conference will also 
look to the future. New challenges for needle exchange 
programmes will always appear, whether they are caused by 
new drugs, changes in injecting habits, or different clients. 
July
8 July 2010
Alcohol 2010: public health, policy and  
personal responsibility
Venue: Central London 
Organised by / Contact: Westminster Forum Projects 
Email: info@westminsterforumprojects.co.uk 
www.westminsterforumprojects.co.uk
Information: This seminar will take a current look at the 
effectiveness of alcohol strategies and media campaigns and 
consider what more could be done to reduce alcohol misuse 
and alcohol-related harm. The agenda will include discussion 
on proposals for minimum pricing and changes to current 
licensing laws. Keynote presentations will be made by expert 
speakers from a range of organisations, including Diageo 
GB, NICE, BMA, Alcohol Concern, Drinkaware, and the 
advertising industry.  
Upcoming events
Maze and minefield — a grounded theory of opiate self-
detoxification in rural Ireland 
McDonnell A and Van Hout MC 
Drugs and Alcohol Today 2010; 10 (2) 24–31 
www.drugsandalcohol.ie/13146
Opiate use is no longer confined to the greater urban 
context in Ireland, with scant detoxification services 
present in rural areas (Carew et al, 2009; National Advisory 
Committee on Drugs, 2008). This exploratory research aimed 
to yield an illustrative account of opiate users' experiences of 
self-detoxification by adopting a grounded theory approach 
(Glaser & Strauss, 1967). Data emerging from 21 in-depth 
interviews (n=12 heroin users, n=9 drug service providers: 
statutory, community and voluntary) were analysed using 
the constant comparative method. The study generated 
a substantive theory of self-detoxification as a subjective 
process of seeking heroin abstinence. Self-detoxification 
emerged as a frequent and reactive or proactive process 
in collaboration with others (heroin users, family and drug 
service providers). The study has implications for drug service 
delivery in rural Ireland in terms of increasing information 
provision and access to opiate detoxification through the 
development of low threshold services and community-
based detoxification.
Primary medical care in Irish prisons
Barry JM, Darker CD, Thomas DE, Allwright SP and  
O’Dowd T  
BMC Health Services Research 2010; 10:74 
www.drugsandalcohol.ie/13086
Background: An industrial dispute between prison doctors 
and the Irish Prison Service (IPS) took place in 2004. Part 
of the resolution of that dispute was that an independent 
review of prison medical and support services be carried out 
by a University Department of Primary Care. The review took 
place in 2008 and we report here on the principal findings of 
that review. 
Methods: This study utilised a mixed methods approach. An 
independent expert medical evaluator (one of the authors, 
DT) inspected the medical facilities, equipment and relevant 
custodial areas in eleven of the fourteen prisons within the 
IPS. Semi-structured interviews took place with personnel 
who had operational responsibility for delivery of prison 
medical care. Prison doctors completed a questionnaire to 
elicit issues such as allocation of clinician’s time, nurse and 
administrative support and resources available. 
Results: There was wide variation in the standard of medical 
facilities and infrastructure provided across the IPS. The range 
of medical equipment available was generally below that of 
the equivalent general practice scheme in the community. 
There is inequality within the system with regard to the ratio 
of doctor-contracted time relative to the size of the prison 
population. There is limited administrative support, with the 
majority of prisons not having a medical secretary. There are 
few psychiatric or counselling sessions available. 
Conclusions: People in prison have a wide range of medical 
care needs and there is evidence to suggest that these needs 
are being met inconsistently in Irish prisons.
(Compiled by Louise Farragher)
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15 July 2010
Masterclass: Beyond mephedrone – the continued rise of 
new psychoactive ‘internet’ drugs
Venue: Vauxhall, London SW8 
Organised by / Contact: Drink and Drugs News /  
CJ Wellings Ltd 
Email: charlotte@cjwellings.com 
www.drinkanddrugsnews.com/ListDiary.aspx
Information: As mephedrone joins the legion of illegal 
drugs, drug users who don’t wish to break the law are 
moving further into unknown territory than ever before. A 
vast array of RCs (research chemicals) are being sold and 
bought over the internet – Move over m-cat, here comes 
naphyrone (NRG-1), 5-IAI, sub-coca dragon 3, Benzo- fury 
(6-APDB), AMT, MDAI and of course NRG-2. Come and join 
the people who predicted the mephedrone phenomenon 
and join us as we look into the future of drug use in the UK.
20–22 July 2010
Intoxicants and intoxication in historical and  
cultural perspective
Venue: Christ’s College Cambridge 
Convenors: Dr Phil Withington; Dr Angela McShane 
Email: pjw1003@cam.ac.uk    a.mcshane@vam.ac.uk 
www.hist.cam.ac.uk/academic_staff/projects/
Information: This three-day conference is hosted by the 
network of the same name, funded by the Economic and 
Social Research Council (ESRC) and supported by the Victoria 
& Albert Museum and the University of Cambridge. The 
aim of the network and of the conference is to gain some 
perspective on the nature and scope of intoxicants and 
intoxication as enduring and ubiquitous social and cultural 
phenomena, by bringing together scholars whose interests 
and expertise range across disciplines, geographies and time 
periods. 
September
23 September 2010
Social work and substance use: evidence-based practice?
Venue: Resource Centre, Holloway Road, Islington, London N7  
Organised by / Contact: Tilda Goldberg Centre, Institute of 
Applied Social Research, University of Bedfordshire 
Email: kerry.lapworth@beds.ac.uk 
www.beds.ac.uk/research/iasr/
Information: This collaborative event includes expert 
speakers from the fields of social work and substance 
use. There will be plenary presentations and interactive 
workshops including the following topics: What does the 
evidence say?; Working with children, parents and family 
members; Domestic violence; Mental health, Older alcohol 
users; Hep C and HIV; Service user involvement; Adolescent 
substance use; Family drug and alcohol courts; Supervising 
social workers in drug and alcohol work; Working partnership 
with specialist services. 
30 September – 2 October 2010
21st Annual ESSD Conference
Venue: Dubrovnik, Croatia 
Organised by / Contact: European Society for Social Drug 
Research / Anita Bošnjak  
Email: essd.dubrovnik@gmail.com 
www.essd-research.eu/en/index.html
Information: Twenty ESSD conferences have been held to 
date, in 16 European countries. The 21st conference will be 
held this year in the Centre for Advanced Academic Studies at 
the University of Zagreb in Dubrovnik, Croatia. Themes to be 
covered include: new drugs; polydrug use; drug-using lifestyles 
and music; drug markets; methodological perspectives in drug 
research; and theories, concepts and analysis. 
At the first ESSD conference in 1990, nearly all the 
participants took an active role and presented their 
own research. This active participation has remained a 
characteristic feature of ESSD conferences and means 
that participants can actively and effectively share their 
experiences with their colleagues across Europe. There are 
no parallel sessions nor workshops and all presentations last 
for 15 minutes. After each two presentations, there are 15 
minutes for discussion. This conference format has clearly 
enhanced the quality of discussions and facilitated the 
exchange of ideas and experiences. Such an atmosphere 
is also less threatening for participants new to the field, 
especially young and new researchers.  
October
4–7 October 2010
12th annual ISAM conference: Bridging the gap between 
science and practice in the addiction field
Venue: University of Milano-Bicocca, Italy 
Organised by / Contact: International Society of Addiction 
Medicine (ISAM) 
Email: isam2010@unimib.it 
www.isam2010.medicina.unimib.it
Information: ISAM Milan 2010 aims to give physicians and 
allied health professionals who treat patients with substance 
use a comprehensive overview of all evidence-based 
findings currently available. The conference will focus on 
the latest scientific developments in addiction medicine and 
addiction psychiatry. The meeting is structured to encourage 
international interaction between clinicians from multiple 
disciplines, schools of thought, and settings. Conference 
events include plenary lectures, symposia, workshops, and 
poster sessions showcasing new research in the field.
7–8 October 2010
National conference on injecting drug use (NCIDU)
Venue: The Sage, Newcastle, UK 
Organised by / Contact: Exchange Supplies 
Email: info@exchangesupplies.org 
www.exchangesupplies.org
Information: A packed and varied programme with over 30 
parallel sessions, meetings, poster presentations and films 
to inform practice, disseminate research, explore policy and 
develop skills. What can you present? If you would like to 
present a paper or workshop session on a subject relevant to 
the conference themes, please see full abstract submission 
details, event information and online booking on our 
website, or call 01305 262244.
Upcoming events (continued)
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3 November 2010
Facing the future: tackling drugs in the new decade 
Venue: NCVO HQ, Regent’s Wharf, London N1 9RL 
Organised by / Contact: DrugScope 
Email: cherylf@drugscope.org.uk 
www.drugscope.org.uk
Information: We have entered a changed economic and 
political landscape. Cuts in public spending are under way, 
with the expectation that services will need to do more for 
less. The ‘localism’ agenda will likely see a shift in decision 
making from central government to local communities. 
The rise in the use of legal highs has led to calls for a 
review of legislation and for faster responses to new and 
emerging drugs. Speakers at DrugScope’s annual conference 
will explore the effects of these changes. How will wider 
economic and political changes impact on drug policy? 
Will we see more attention paid to tackling alcohol misuse? 
Will drug and alcohol crime and health policies draw closer 
together? What are the risks and potential opportunities for 
the drug sector? 
4–5 November 2010
National Drugs Conference: Continuum of care within  
drug services
Venue: Radisson Blu Royal Hotel, Dublin 8 
Organised by / Contact: Irish Needle Exchange Forum 
(INEF) and others 
Email: conference2010@inef.ie  
http://inef.ie
Information: It was clear that the INEF conference in 
November 2009 benefited from the range of disciplines 
within the delegate group. Building on this experience, 
and under the guidance of the INEF Advisory Group (made 
up of members of the voluntary and statutory sectors), the 
INEF has come together with the Irish Association of Alcohol 
and Addiction Counsellors (IAAAC), Ana Liffey Drug Project 
and Coolmine Therapeutic Community to hold a National 
Drugs Conference. The conference will include national and 
international speakers from across the spectrum of service 
provision and policy development, i.e. this is not a harm- 
reduction conference or an abstinence-based conference; 
this is an all-inclusive drugs conference. 
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